WO2001055301A2 - Acides nucleiques, proteines et anticorps - Google Patents

Acides nucleiques, proteines et anticorps Download PDF

Info

Publication number
WO2001055301A2
WO2001055301A2 PCT/US2001/001239 US0101239W WO0155301A2 WO 2001055301 A2 WO2001055301 A2 WO 2001055301A2 US 0101239 W US0101239 W US 0101239W WO 0155301 A2 WO0155301 A2 WO 0155301A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
polypeptide
sequence
polynucleotide
column
Prior art date
Application number
PCT/US2001/001239
Other languages
English (en)
Other versions
WO2001055301A8 (fr
WO2001055301A3 (fr
Inventor
Craig A. Rosen
Steven C. Barash
Steven M. Ruben
Original Assignee
Human Genome Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences, Inc. filed Critical Human Genome Sciences, Inc.
Priority to AU2001252878A priority Critical patent/AU2001252878A1/en
Priority to AU5287801A priority patent/AU5287801A/xx
Priority to US09/908,711 priority patent/US20020045230A1/en
Publication of WO2001055301A2 publication Critical patent/WO2001055301A2/fr
Publication of WO2001055301A8 publication Critical patent/WO2001055301A8/fr
Publication of WO2001055301A3 publication Critical patent/WO2001055301A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided. encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function ofthe polypeptides ofthe present invention.
  • Enzymes comprise a large subset of proteins which function as catalysts for biochemical reactions. In fact, virtually every biochemical reaction mvolves the catalytic activity of an enzyme or enzymes. Most enzymes are located intracellularly, but there are a number of enzyme families which are either secreted into the extracellular space, or associated with the plasma membrane. Some enzymes, including the secreted digestive enzymes trypsin and pepsin, are produced as inactive precursors called zymogens, which require chemical modification to become active. In many cases, the catalytic activity of an enzyme depends on its association with a cofactor. Cofactors may be organic molecules, termed coenzymes, or metal ions. Many coenzymes are derived from vitamins.
  • Enzymes contain two important functional units: the substrate binding site, and the catalytic site.
  • the substrate-binding site consists of a cleft which is geometrically complementary to the shape of the preferred substrate.
  • the amino acid residues which form the substrate binding site have noncovalent interactions with the amino acids of the complementary substrate region.
  • the catalytic site is the portion of the molecule that facilitates the biochemical reaction once the substrate is bound to the enzyme.
  • IUBMB International Union of Biochemistry and Molecular Biology
  • EC [A.B.C.D] is one ofthe major functional classes of enzymes (1 through 6; see below); B and C designate increasingly specific subgroups of enzymatic reactions; and D represents the arbitrary number of an individual member of a given category.
  • the enzyme acetylcholinesterase is designated EC 3.1.1.7, because it is a member of the class of hydrolases (EC 3.-.-.-), acting on ester bonds (EC 3.1.-.-), in the subgroup of carboxylic ester hydrolases (EC 3.1.1.-), and it is assigned number 7. Descriptions of the six major functional classes, including notable examples of each, follow below.
  • Oxidoreductases (EC 1.-.-.-)
  • Enzymes of this class catalyze oxidation-reduction reactions. Sub-classification is according to the substrate group oxidized (e.g., CH-OH, CH-CH, and CH-NH 2 , to name but a few).
  • a representative member of this enzyme class is long-chain-alcohol dehydrogenase (EC 1.1.1.192), which is involved in lipid metabolism. Deficient activity of this enzyme has been shown to be the primary cause of Sjogren-Larsson syndrome, an autosomal recessive disorder characterized by the presence of ichthyosis, mental retardation, and spasticity (Rizzo et al, J. Clin. Invest. 81: 738-744 (1988).
  • Transferases are characterized by the transfer of a chemical group from a "donor" molecule to an "acceptor” molecule. Transferases can be subgrouped according to the chemical group transferred. For example, amino transferases (EC 2.6.-.-) transfer nitrogenous groups, and methyltranferases (EC 2.1.1.-) transfer methyl groups. Often the transferred group is donated by a coenzyme.
  • a major subgroup of transferase enzymes are the protem kinases (EC 2.7.-.-), which catalyze the transfer of a phosphate group from ATP to a substrate protein.
  • Protem kinases such as calcium/calmodulin dependent (CaM) kinase II (EC 2.7.1.123), are known to play important roles in signal transduction pathways (Kennedy , Brain Res Brain Res Rev 26(2-3):243-57 (1998)).
  • Other transferases are involved in metabolic processes. For example, guanidinoacetate N- methyltransferase (GAMT; EC 2.1.1.2), converts guanidinoacetate into creatine, which is essential for the maintenance of energy reserves in the form of ATP.
  • GAMT deficiency causes neurological impairments which may include progressive extrapyramidal movement disorders, seizures, developmental delay, and muscular dystonia (Stockier et al., Pediat. Res. 36:409-413 (1994).
  • Hydrolases EC 3.-.-.-
  • Enzymes of this class catalyze the splitting of a substrate into two fragments by the addition of a water molecule; the water's hydroxyl group being incorporated in one fragment and the hydrogen atom in the other.
  • Hydrolases can be subcategorized according to the chemical bond involved.
  • peptidases EC 3.4.-.-; also known as proteases
  • Pepsin EC 3.4.23.1
  • a digestive protease which has been implicated in a number of gastrointestinal disorders, is an example of a proteolytic hydrolase enzyme (see, for example, Hirschowitz, Yale J. Biol. Med.
  • Gaucher's disease Symptoms of Gaucher's disease include bone lesions, skin pigmentation, enlargement of the liver and spleen, and, in some cases, neurological impairments.
  • Lyases cleave C-C, C-O, C-N, and other bonds by means other than hydrolysis or oxidation.
  • the reverse reaction is performed by a synthetase.
  • Histidine decarboxylase (EC 4.1.1.22) is a carboxy-lyase that converts histidine to histamine, a biogenic amine involved in a number of physiologic processes, including inflammation, allergic responses, neurotransmission, and gastric acid secretion.
  • the phosphorus-oxygen lyase adenylate cyclase (EC 4.6.1.1) is an intracellular enzyme which acts on ATP to form adenosine 3' ,5' -cyclic phosphate (cAMP), a second messenger activator of protein kinase activity.
  • cAMP adenosine 3' ,5' -cyclic phosphate
  • isomerases include racemases / epimerases (EC 5.1.-.-.), cis-trans- isomerases (EC 5.2.-.-), intramolecular isomerases (EC 5.3.-.-), intramolecular transferases (EC 5.4.-.-), and intramolecular lyases (EC 5.5.-.-).
  • Protein disulfide isomerase (PDI; EC 5.3.4.1) catalyzes the intramolecular rearrangement of disulfide bonds, thus contributing to the folding of newly-synthesized proteins at the endoplasmic reticulum (see, for example, Luz and Lennarz, EXS 77:97-117 (1996)).
  • Autoantibodies to PDI have been implicated in hepatic disorders (Nagayama et al., J Toxicol Sci Aug; 19(3): 163-9 (1994)).
  • Ligases (EC 6.-.-.-
  • Ligase enzymes catalyze the formation of a bond between two substrate molecules, coupled with the hydrolysis of a pyrophosphate bond in ATP or a similar triphosphate.
  • a well characterized example of this class is DNA ligase 1 (EC 6.5.1.1), which catalyzes the joining of DNA fragments (via the formation of a phosphodiester bond) during DNA replication, recombination, and repair. Mutations in the gene encoding DNA ligase 1 have been linked to immunodeficiency disorders and hypersensitivity to DNA-damaging agents (Barnes et al, Cell, 69, 495-503 (1992)).
  • the present invention relates to novel protems. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function ofthe polypeptides ofthe present invention. Detailed Description Tables
  • the first column provides the gene number in the application for each clone identifier.
  • the second column provides a unique clone identifier, "Clone ID NO:Z", for a cDNA clone related to each contig sequence disclosed in Table 1 A.
  • the third column provides a unique contig identifier, "Contig ID:” for each of the contig sequences disclosed in Table IA.
  • the fourth column provides the sequence identifier, "SEQ ID NO:X", for each of the contig sequences disclosed in Table IA.
  • the fifth column “ORF (From-To)" provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence of SEQ ID NO:X that delineate the preferred open reading frame (ORF) that encodes the amino acid sequence shown in the sequence listing and referenced in Table IA as SEQ ID NO:Y (column 6).
  • Column 7 lists residues comprising predicted epitopes contained in the polypeptides encoded by each of the preferred ORFs (SEQ TD NO:Y).
  • polypeptides of the invention comprise, or alternatively consist of, one, two, three, four, five or more of the predicted epitopes described in Table IA.
  • Tissue Distribution shows the expression profile of tissue, cells, and/or cell line libraries which express the polynucleotides of the invention.
  • the first number in column 8 represents the tissue/cell source identifier code corresponding to the key provided in Table 4. Expression of these polynucleotides was not observed in the other tissues and/or cell libraries tested.
  • the second number in column 8 represents the number of times a sequence corresponding to the reference polynucleotide sequence (e.g., SEQ ID NO:X) was identified in the tissue/cell source.
  • tissue/cell source identifier codes in which the first two letters are "AR” designate information generated using DNA array technology. Utilizing this technology, cDNAs were amplified by PCR and then transferred, in duplicate, onto the array. Gene expression was assayed through hybridization of first strand cDNA probes to the DNA array. cDNA probes were generated from total RNA extracted from a variety of different tissues and cell lines.
  • Probe synthesis was performed in the presence of 33 P dCTP, using oligo(dT) to prime reverse transcription. After hybridization, high stringency washing conditions were employed to remove non-specific hybrids from the array. The remaining signal, emanating from each gene target, was measured using a Phosphorimager. Gene expression was reported as Phosphor Stimulating Luminescence (PSL) which reflects the level of phosphor signal generated from the probe hybridized to each ofthe gene targets represented on the array. A local background signal subtraction was performed before the total signal generated from each array was used to normalize gene expression between the different hybridizations. The value presented after "[array code]:" represents the mean of the duplicate values, following background subtraction and probe normalization.
  • PSL Phosphor Stimulating Luminescence
  • OMIM Disease Reference(s) A key to the OMIM reference identification numbers is provided in Table 5.
  • the first column provides a unique clone identifier, "Clone ID NO:Z”, for a cDNA clone related to each contig sequence.
  • the second column provides the sequence identifier, "SEQ ID NO:X”, for each contig sequence.
  • the third column provides a unique contig identifier, "Contig ID:” for each contig sequence.
  • the fourth column provides a BAC identifier "BAC ID NO:A” for the BAC clone referenced in the corresponding row of the table.
  • the fifth column provides the nucleotide sequence identifier, "SEQ ID NO:B" for a fragment of the BAC clone identified in column four of the corresponding row of the table.
  • the sixth column provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence of SEQ ID NO:B which delineate certain polynucleotides of the invention that are also exemplary members of polynucleotide sequences that encode polypeptides of the invention (e.g., polypeptides containing amino acid sequences encoded by the polynucleotide sequences delineated in column six, and fragments and variants thereof).
  • Table 2 summarizes homology and features of some of the polypeptides of the invention.
  • the first column provides a unique clone identifier, "Clone ID NO:Z”, corresponding to a cDNA clone disclosed in Table IA.
  • the second column provides the unique contig identifier, "Contig ID:” corresponding to contigs in Table IA and allowing for correlation with the information in Table IA.
  • the third column provides the sequence identifier, "SEQ ID NO:X”, for the contig polynucleotide sequence.
  • the fourth column provides the analysis method by which the homology/identity disclosed in the Table was determined.
  • NR non-redundant protein database
  • PFAM protein families
  • polypeptides of the invention comprise, or alternatively consist of, an amino acid sequence encoded by a polynucleotide in SEQ ID NO:X as delineated in columns 8 and 9, or fragments or variants thereof.
  • the PFAM identification disclosed in Table 2, columns 5 and 6, communicates both the function and enzymatic activity of polypeptides corresponding to the PFAM.
  • Extensive documentation on PFAM families and individual members of these families are maintained in publicly accessible databases (see, for example the Sanger Centre PFAM web server at http://www.sanger.ac.uk/ for a searchable PFAM database).
  • PROSITE, SWISSPROT, GenBank, and other sequence databases one can routinely assign an EC (Enzyme Commission) code to the polypeptides.
  • the EC code consists of 4 integers separated by decimal points that are used to classify enzymes, and indicate important information about cellular function and enzyme mechanism.
  • the third digit is used to distinguish further characteristics (EC 1.1.1 oxidoreductases acting on the CH-OH group of donors with NAD or NADP as the acceptor, versus EC 1.1.2 where a cytochrome acts as the acceptor) or is simply assigned as 1 for the all entries where further clarification is unnecessary (all members of EC 4.1, carbon-carbon lyases are in group 4.1.1).
  • the final number designates a specific enzyme, for instance, EC 4.1.1.1 pyruvate decarboxylase, or EC 1.1.1.1 alcohol dehydrogenase.
  • the polypeptide being evaluated is likely to have a similar EC code, and, in this example, will likely be an oxidoreductase acting on the CH-OH group of donors with oxygen as an acceptor.
  • the first column provides a unique clone identifier, "Clone ID”, for a cDNA clone related to contig sequences disclosed in Table IA.
  • the second column provides the sequence identifier, "SEQ ID NO:X”, for contig sequences disclosed in Table IA.
  • the third column provides the unique contig identifier, "Contig JJD:”, for contigs disclosed in Table IA.
  • the fourth column provides a unique integer 'a' where 'a' is any integer between 1 and the final nucleotide minus 15 of SEQ ID NO:X
  • the fifth column provides a unique integer 'b' where 'b' is any integer between 15 and the final nucleotide of SEQ ID NO:X, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:X, and where b is greater than or equal to a + 14.
  • the uniquely defined integers can be substituted into the general formula of a-b, and used to describe polynucleotides which may be preferably excluded from the invention.
  • preferably excluded from the invention are at least one, two, three, four, five, ten, or more of the polynucleotide sequence(s) having the accession number(s) disclosed in the sixth column of this Table (including for example, published sequence in connection with a particular BAC clone).
  • preferably excluded from the invention are the specific polynucleotide sequence(s) contained in the clones corresponding to at least one, two, three, four, five, ten, or more of the available material having the accession numbers identified in the sixth column of this Table (including for example, the actual sequence contained in an identified BAC clone).
  • Table 4 provides a key to the tissue/cell source identifier code disclosed in Table
  • tissue/cell source identifier code disclosed in Table IA, Column 8.
  • Columns 2-5 provide a description of the tissue or cell source. Codes corresponding to diseased tissues are indicated in column 6 with the word "disease". The use of the word "disease" in column 6 is non-limiting.
  • the tissue or cell source may. be specific (e.g. a neoplasm), or may be disease-associated (e.g., a tissue sample from a normal portion of a diseased organ).
  • tissues and/or cells lacking the "disease" designation may still be derived from sources directly or indirectly involved in a disease state or disorder, and therefore may have a further utility in that disease state or disorder.
  • column 7 identifies the vector used to generate the library.
  • Table 5 provides a key to the OMIM reference identification numbers disclosed in Table IA, column 10.
  • OMIJVI reference identification numbers (Column 1) were derived from Online Mendelian Inheritance in Man (Online Mendelian Inheritance in Man, OMIM.
  • Table 6 summarizes ATCC Deposits, Deposit dates, and ATCC designation numbers of deposits made with the ATCC in connection with the present application.
  • Table 7 shows the cDNA libraries sequenced, and ATCC designation numbers and vector information relating to these cDNA libraries.
  • Table 8 provides a physical characterization of clones encompassed by the invention.
  • the first column provides the unique clone identifier, "Clone ID NO:Z", for certain cDNA clones of the invention, as described in Table IA.
  • the second column provides the size ofthe cDNA insert contained in the corresponding cDNA clone.
  • isolated refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered “by the hand of man” from its natural state.
  • an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be “isolated” because that vector,, composition of matter, or particular cell is not the original environment ofthe polynucleotide.
  • isolated does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by electrophoresis and transferred onto blots), sheared whole cell genomic DNA preparations or other compositions where the art demonstrates no distinguishing features ofthe polynucleotide/sequences ofthe present invention.
  • a "polynucleotide” refers to a molecule having a nucleic acid sequence encoding SEQ ID NO:Y or a fragment or variant thereof; a nucleic acid sequence contained in SEQ JD NO:X (as described in column 3 of Table IA) or the complement thereof; a cDNA sequence contained in Clone ID NO:Z (as described in column 2 of Table IA and contained within a library deposited with the ATCC); a nucleotide sequence encoding the polypeptide encoded by a nucleotide sequence in SEQ ID NO:B as defined in column 6 of Table IB or a fragment or variant thereof; or a nucleotide coding sequence in SEQ ID NO:B as defined in column 6 of Table IB or the complement thereof.
  • the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, as well as fragments, epitopes, domains, and variants ofthe nucleic acid sequence.
  • a "polypeptide” refers to a molecule having an amino acid sequence encoded by a polynucleotide ofthe invention as broadly defined (obviously excluding poly-Phenylalanine or poly-Lysine peptide sequences which result from translation of a polyA tail of a sequence corresponding to a cDNA).
  • SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig analysis).
  • a representative clone containing all or most ofthe sequence for SEQ ID NO:X is deposited at Human Genome Sciences, Inc. (HGS) in a catalogued and archived library.
  • HGS Human Genome Sciences, Inc.
  • each clone is identified by a cDNA Clone ID (identifier generally referred to herein as Clone ID NO:Z).
  • Clone ID NO:Z identifier generally referred to herein as Clone ID NO:Z.
  • Each Clone ID is unique to an individual clone and the Clone ID is all the information needed to retrieve a given clone from the HGS library.
  • ATCC American Type Culture Collection
  • Library names contain four characters, for example, "HTWE.”
  • the name of a cDNA clone (Clone ID) isolated from that library begins with the same four characters, for example "HTWEP07".
  • Table IA correlates the Clone ID names with SEQ ID NO:X.
  • SEQ ID NO:X the Clone ID names with SEQ ID NO:X.
  • the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length.
  • polynucleotides of the invention comprise a portion of the coding sequences, as disclosed herein, but do not comprise all or a portion of any intron.
  • the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome).
  • the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).
  • a "polynucleotide” of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, or the complement thereof (e.g., the complement of any one, two, three, four, or more of the polynucleotide fragments described herein), the polynucleotide sequence delineated in columns 8 and 9 of Table 2 or the complement thereof, and/or cDNA sequences contained in Clone ID NO:Z (e.g., the complement of any one, two, three, four, or more ofthe polynucleotide fragments, or the cDNA clone within the pool of cDNA clones deposited with the ATCC, described herein), and/or the polynucleotide sequence delineated in column 6 of Table IB or the complement thereof.
  • “Stringent hybridization conditions” refers to an overnight incubation at 42 degree C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 ⁇ g/ml denatured, sheared salmon sperm DNA, followed by washing the filters in O.lx SSC at about 65 degree C.
  • nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions.
  • Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature.
  • washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).
  • blocking reagents used to suppress background in hybridization experiments.
  • Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations.
  • the inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.
  • polynucleotide which hybridizes only to polyA+ sequences (such as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide,” since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double- stranded cDNA clone generated using oligo dT as a primer).
  • the polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA.
  • polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions.
  • polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA.
  • a polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons.
  • Modified bases mclude, for example, tritylated bases and unusual bases such as inosine.
  • a variety of modifications can be made to DNA and RNA; thus, "polynucleotide” embraces chemically, enzymatically, or metabolically modified forms.
  • the polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids.
  • the polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini.
  • polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods.
  • Modifications include acetylation, acylation, ADP- ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.
  • SEQ ID NO:X refers to a polynucleotide sequence described, for example, in
  • SEQ ID NO:Y refers to a polypeptide sequence described in column 6 of Table IA.
  • SEQ ID NO:X is identified by an integer specified in column 4 of Table IA.
  • the polypeptide sequence SEQ ID NO:Y is a translated open reading frame (ORF) encoded by polynucleotide SEQ ID NO:X.
  • Clone ID NO:Z refers to a cDNA clone described in column 2 of Table IA.
  • a polypeptide having functional activity refers to a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) protein. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a polypeptide for binding) to an anti- polypeptide antibody], immunogenicity (ability to generate antibody which binds to a specific polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide.
  • PFAM accession number disclosed in Table 2 column 6 provides a link, through publicly accessible databases (see, for example the Sanger Centre PFAM web server at http://www.sanger.ac.uk/, and included links to PROSITE, SWISSPROT, GenBank, and other sequence databases), to the associated EC code, or closely-related EC codes.
  • EC codes provide a description of the biochemical reaction(s) catalyzed by an enzyme family. Based on the associated EC code(s), one can routinely test the polypeptides of the invention for functional activity (e.g. biological activity) using or routinely modifying assays known in the art and/or assays described herein.
  • a polypeptide having biological activity refers to a polypeptide exhibiting activity similar to, but not necessarily identical to, an activity of a polypeptide ofthe present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency.
  • the first column in Table IA provides the gene number in the application corresponding to the clone identifier.
  • the second column in Table IA provides a unique "Clone ID NO:Z" for a cDNA clone related to each contig sequence disclosed in Table 1 A.
  • This clone ID references the cDNA clone which contams at least the 5' most sequence of the assembled contig and at least a portion of SEQ ID NO:X was determined by directly sequencing the referenced clone.
  • the reference clone may have more sequence than described in the sequence listing or the clone may have less. In the vast majority of cases, however, the clone is believed to encode a full-length polypeptide. hi the case where a clone is not full-length, a full-length cDNA can be obtained by methods described elsewhere herein.
  • the third column in Table IA provides a unique "Contig ID” identification for each contig sequence.
  • the fourth column provides the "SEQ ID NO:” identifier for each of the contig polynucleotide sequences disclosed in Table IA.
  • the fifth column, "ORF (From-To)" provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence "SEQ ID NO:X” that delineate the preferred open reading frame (ORF) shown in the sequence listing and referenced in Table IA, column 6, as SEQ ID NO:Y. Where the nucleotide position number "To" is lower than the nucleotide position number "From”, the preferred ORF is the reverse complement of the referenced polynucleotide sequence.
  • the sixth column in Table 1 A provides the corresponding SEQ ID NO:Y for the polypeptide sequence encoded by the preferred ORF delineated in column 5.
  • the invention provides an amino acid sequence comprising, or alternatively consisting of, a polypeptide encoded by the portion of SEQ ID NO:X delineated by "ORF (From-To)". Also provided are polynucleotides encoding such amino acid sequences and the complementary strand thereto.
  • polypeptides ofthe invention comprise, or alternatively consist of, at least one, two, three, four, five or more ofthe predicted epitopes as described in Table IA.
  • Column 8 in Table IA provides an expression profile and library code: count for each ofthe contig sequences (SEQ ID NO:X) disclosed in Table 1 A, which can routinely be combined with the info ⁇ nation provided in Table 4 and used to determine the tissues, cells, and/or cell line libraries which predominantly express the polynucleotides of the invention.
  • the first number in column 8 represents the tissue/cell source identifier code corresponding to the code and description provided in Table 4.
  • the second number in column 8 represents the number of times a sequence corresponding to the reference polynucleotide sequence was identified in the tissue/cell source.
  • tissue/cell source identifier codes in which the first two letters are "AR” designate information generated using DNA array technology. Utilizing this technology, cDNAs were amplified by PCR and then transferred, in duplicate, onto the array. Gene expression was assayed through hybridization of first strand cDNA probes to the DNA array. cDNA probes were generated from total RNA extracted from a variety of different tissues and cell lines. Probe synthesis was performed in the presence of P dCTP, using oligo(dT) to prime reverse transcription.
  • Chromosomal mapping data is often available for one or more sequence(s) in a UniGene cluster; this data (if consistent) is then applied to the cluster as a whole. Thus, it is possible to infer the chromosomal location of a new polynucleotide sequence by determining its identity with a mapped UniGene cluster.
  • BLASTN Altshul et al., J. Moi.
  • OMIM Disease Reference(s) Table 5 is a key to the OMIM reference identification numbers (column 1), and provides a description of the associated disease in Column 2.
  • the first column provides a unique clone identifier, "Clone ID NO:Z”, for a cDNA clone related to each contig sequence.
  • the second column provides the sequence identifier, "SEQ ID NO:X”, for each contig sequence.
  • the third column provides a unique contig identifier, "Contig ID:” for each contig sequence.
  • the fourth column provides a BAC identifier "BAC ID NO:A” for the BAC clone referenced in the corresponding row of the table.
  • the fifth column provides the nucleotide sequence identifier, "SEQ ID NO:B" for a fragment of the BAC clone identified in column four of the corresponding row of the table.
  • the sixth column provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence of SEQ ID NO:B which delineate certain polynucleotides of the invention that are also exemplary members of polynucleotide sequences that encode polypeptides of the invention (e.g., polypeptides containing amino acid sequences encoded by the polynucleotide sequences delineated in column six, and fragments and variants thereof).
  • Table 2 further characterizes certain encoded polypeptides of the invention, by providing the results of comparisons to protem and protem family databases.
  • the first column provides a unique clone identifier, "Clone ID NO:”, corresponding to a cDNA clone disclosed in Table IA.
  • the second column provides the unique contig identifier, "Contig ID:” which allows correlation with the information in Table IA.
  • the third column provides the sequence identifier, "SEQ ID NO:”, for the contig polynucleotide sequences.
  • the fourth column provides the analysis method by which the homology/identity disclosed in the Table was determined.
  • the fifth column provides a description of the PFAM/NR hit identified by each analysis.
  • the NR database which comprises the NBRF Pffi. database, the NCBI GenPept database, and the SIB SwissProt and TrEMBL databases, was made non-redundant using the computer program nrdb2 (Warren Gish, Washington University in Saint Louis).
  • nrdb2 Warren Gish, Washington University in Saint Louis.
  • Each of the polynucleotides shown in Table IA, column 3 e.g., SEQ ID NO:X or the 'Query' sequence
  • the computer program BLASTX was used to compare a 6-frame translation of the Query sequence to the NR database (for information about the BLASTX algorithm please see Altshul et al., J. Moi. Biol. 215:403- 410 (1990); and Gish and States, Nat.
  • the percent identity is determined by dividing the number of exact matches between the two aligned sequences in the HSP, dividing by the number of Query amino acids in the HSP and multiplying by 100.
  • the polynucleotides of SEQ ID NO:X which encode the polypeptide sequence that generates an HSP are delineated by columns 8 and 9 of Table 2.
  • HMM Hidden Markov Model
  • a HMM derived from PFAM version 2.1 was said to be a significant match to a polypeptide of the invention if the score returned by HMMER 1.8 was greater than 0.8 times the HMMER 1.8 score obtained with the most distantly related known member of that protem family.
  • the description ofthe PFAM family which shares a significant match with a polypeptide of the invention is listed in column 5 of Table 2, and the database accession number of the PF.AM hit is provided in column 6.
  • Column 7 provides the score returned by HMMER version 1.8 for the alignment.
  • Columns 8 and 9 delineate the polynucleotides of SEQ ID NO:X which encode the polypeptide sequence which show a significant match to a PFAM protem family.
  • the invention provides a protein comprising, or alternatively consisting of, a polypeptide encoded by the polynucleotides of SEQ ID NO:X delineated in columns 8 and 9 of Table 2. Also provided are polynucleotides encoding such proteins, and the complementary strand thereto.
  • nucleotide sequence SEQ ID NO:X and the translated SEQ ID NO:Y are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below.
  • the nucleotide sequences of SEQ ID NO:X are useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in Clone ID NO:Z. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling immediate applications in chromosome mapping, linkage analysis, tissue identification and/or typing, and a variety of forensic and diagnostic methods ofthe invention.
  • polypeptides identified from SEQ ID NO:Y may be used to generate antibodies which bind specifically to these polypeptides, or fragments thereof, and/or to the polypeptides encoded by the cDNA clones identified in, for example, Table 1 A.
  • DNA sequences generated by sequencing reactions can contain sequencing errors.
  • the errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence.
  • the erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence.
  • the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).
  • the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X, and a predicted translated amino acid sequence identified as SEQ ID NO: Y, but also a sample of plasmid DNA containing cDNA Clone ID NO:Z (deposited with the ATCC on October 5, 2000, and receiving ATCC designation numbers PTA 2574 and PTA 2575; deposited with the ATCC on January 5, 2001, and having depositor reference numbers TS-1, TS-2, AC-1, and AC-2; and/or as set forth, for example, in Table IA, 6 and 7).
  • the nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods. Further, techniques known in the art can be used to verify the nucleotide sequences of SEQ ID NO:X.
  • amino acid sequence ofthe protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.
  • Partial cDNA clones can be made full-length by utilizing the rapid amplification of cDNA ends (RACE) procedure described in Frohman, M.A., et al., Proc. Nat'l. Acad. Sci. USA, 85:8998-9002 (1988).
  • RACE rapid amplification of cDNA ends
  • RNA Poly A+ or total RNA is reverse transcribed with Superscript II (Gibco/BRL) and an antisense or complementary primer specific to the cDNA sequence.
  • the primer is removed from the reaction with a Microcon Concentrator (Amicon).
  • the first-strand cDNA is then tailed with dATP and terminal deoxynucleotide transferase (Gibco/BRL).
  • the second strand is synthesized from the dA-tail in PCR buffer, Taq DNA polymerase (Perkin-Elmer Cetus), an oligo-dT primer containing three adjacent restriction sites (Xhol, Sail and Clal) at the 5' end and a primer containing just these restriction sites.
  • This double-stranded cDNA is PCR amplified for 40 cycles with the same primers as well as a nested cDNA-specific antisense primer.
  • the PCR products are size-separated on an ethidium bromide-agarose gel and the region of gel containing cDNA products the predicted size of missing protein-coding DNA is removed.
  • cDNA is purified from the agarose with the Magic PCR Prep kit (Promega), restriction digested with Xhol or Sail, and ligated to a plasmid such as pBluescript SKII (Stratagene) at Xhol and EcoRV sites.
  • This DNA is transformed into bacteria and the plasmid clones sequenced to identify the correct protein-coding inserts. Correct 5' ends are confirmed by comparing this sequence with the putatively identified homologue and overlap with the partial cDNA clone. Similar methods known in the ajrt and/or commercial kits are used to amplify and recover 3' ends.
  • kits are commercially available for purchase. Similar reagents and methods to those above are supplied in kit form from Gibco/BRL for both 5' and 3' RACE for recovery of full length genes. A second kit is available from Clontech which is a modification of a related technique, SLIC (single-stranded ligation to single- stranded cDNA), developed by Dumas et al., Nucleic Acids Res., 19:5227-32 (1991). The major differences in procedure are that the RNA is alkaline hydrolyzed after reverse transcription and RNA ligase is used to join a restriction site-containing anchor primer to the first-strand cDNA. This obviates the necessity for the dA-tailing reaction which results in a polyT stretch that is difficult to sequence past.
  • SLIC single-stranded ligation to single- stranded cDNA
  • An alternative to generating 5' or 3' cDNA from RNA is to use cDNA library double-stranded DNA.
  • An asymmetric PCR-amplified antisense cDNA strand is synthesized with an antisense cDNA-specific primer and a plasmid-anchored primer. These primers are removed and a symmetric PCR reaction is performed with a nested cDNA- specific antisense primer and the plasmid-anchored primer.
  • RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcript and a primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest, is used to PCR amplify the 5' portion of the desired full length gene which may then be sequenced and used to generate the full length gene.
  • This method starts with total RNA isolated from the desired source, poly A RNA may be used but is not a prerequisite for this procedure.
  • RNA preparation may then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step.
  • the phosphatase if used is then inactivated and the RNA is treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs.
  • This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.
  • This modified RNA preparation can then be used as a template for first strand cDNA synthesis using a gene specific oligonucleotide.
  • the first strand synthesis - reaction can then be used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest.
  • the resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the relevant gene.
  • the present invention also relates to vectors or plasmids which include such
  • the material deposited with the ATCC (deposited with the ATCC on October 5, 2000, and receiving ATCC designation numbers PTA 2574 and PTA 2575; deposited with the ATCC on January ' 5, 2001, and receiving ATCC designation numbers TS-1, TS-2, AC-1, and AC-2; and/or as set forth, for example, in Table IA, Table 6, or Table 7) is a mixture of cDNA clones derived from a variety of human tissue and cloned in either a plasmid vector or a phage vector, as described, for example, in Table 7. These deposits are referred to as "the deposits" herein.
  • the tissues from which some ofthe clones were derived are listed in Table 7, and the vector in which the corresponding cDNA is contained is also indicated in Table 7.
  • the deposited material includes cDNA clones corresponding to SEQ ID NO:X described, for example, in Table 1 A (Clone ID NO:Z).
  • a clone which is isolatable from the ATCC Deposits by use of a sequence listed as SEQ ID NO:X may include the entire coding region of a human gene or in other cases such clone may include a substantial portion of the coding region of a human gene.
  • sequence listing may in some instances list only a portion of the DNA sequence in a clone included in the ATCC Deposits, it is well within the ability of one skilled in the art to sequence the DNA included in a clone contained in the ATCC Deposits by use of a sequence (or portion thereof) described in, for example Tables lAor 2 by procedures hereinafter further described, and others apparent to those skilled in the art.
  • Table 7 Also provided in Table 7 is the name of the vector which contains the cDNA clone. Each vector is routinely used in the art. The following additional information is provided for convenience.
  • pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene.
  • Phagemid pBS may be excised from the Lambda Zap and Uni-Zap XR vectors, and phagemid pBK may be excised from the Zap Express vector. Both phagemids may be transformed into E. coli strain XL-1 Blue, also available from Stratagene.
  • Vectors pSportl, pCMVSport 1.0, pCMVSport 2.0 and pCMVSport 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies.
  • Vector lafmid BA (Bento Soares, Columbia University, New York, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue.
  • Vector pCR ® 2.1 which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. See, for instance, Clark, J. M., Nuc. Acids Res. 16:9611-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).
  • the present invention also relates to the genes corresponding to S ⁇ Q ID NO:X,
  • S ⁇ Q ID NO:Y and/or the deposited clone (Clone ID NO:Z).
  • the corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.
  • allelic variants, orthologs, and/or species homologs are also provided in the present invention. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to S ⁇ Q ID NO:X or the complement thereof, polypeptides encoded by genes corresponding to S ⁇ Q ID NO:X or the complement thereof, and/or the cDNA contained in Clone ID NO:Z, using information from the sequences disclosed herein or the clones deposited with the ATCC.
  • allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.
  • polypeptides of the invention can be prepared in any suitable manner.
  • Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.
  • the polypeptides may be in the form ofthe secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino ' acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.
  • the polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified.
  • a recombinantly produced version of a polypeptide, including the secreted polypeptide can be substantially purified using techniques described herein or otherwise known in the art, such as, for example, by the one- step method described in Smith and Johnson, Gene 67:31-40 (1988).
  • Polypeptides of the invention also can be purified from natural, synthetic or recombinant sources using techniques described herein or otherwise known in the art, such as, for example, antibodies of the invention raised against the polypeptides of the present invention in methods which are well known in the art.
  • the present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X, and/or the cDNA sequence contained in Clone ID NO:Z.
  • the present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X or a complement thereof, a polypeptide encoded by the cDNA contained in Clone ID NO:Z, and/or the polypeptide sequence encoded by a nucleotide sequence in SEQ ID NO:B as defined in column 6 of Table IB.
  • Polynucleotides encoding a polypeptide comprising, or alternatively consisting of the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X, a polypeptide encoded by the cDNA contained in Clone ID NO:Z, and/or a polypeptide sequence encoded by a nucleotide sequence in SEQ ID NO:B as defined in column 6 of Table IB are also encompassed by the invention.
  • the present invention further encompasses a polynucleotide comprising, or alternatively consisting of, the complement of the nucleic acid sequence of SEQ LD NO:X, a nucleic acid sequence encoding a polypeptide encoded by the complement of the nucleic acid sequence of SEQ ID NO:X, and/or the cDNA contained in Clone ID NO:Z.
  • representative examples of polynucleotides ofthe invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in Table IB column 6, or any combination thereof.
  • polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the complementary strand(s) of the sequences delineated in Table IB column 6, or any combination thereof.
  • the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in Table IB, column 6, and have a nucleic acid sequence which is different from that of the BAC fragment having the sequence disclosed in SEQ ID NO:B (see Table IB, column 5).
  • the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in Table IB, column 6, and have a nucleic acid sequence which is different from that published for the BAC clone identified as BAC ID NO:A (see Table IB, column 4). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in Table IB, column 6, and have a nucleic acid sequence which is different from that contained in the BAC clone identified as BAC ID NO:A (see Table IB, column 4).
  • Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides and polypeptides are also encompassed by the invention.
  • representative examples of polynucleotides ofthe invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more ofthe sequences delineated in column 6 of Table IB which correspond to the same Clone ID NO:Z (see Table IB, column 1), or any combination thereof.
  • Additional, representative examples of polynucleotides ofthe invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the complementary strand(s) of the sequences delineated in column 6 of Table IB which correspond to the same Clone ID NO:Z (see Table IB, column 1), or any combination thereof.
  • the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table IB which correspond to the same Clone ID NO:Z (see Table IB, column 1) and have a nucleic acid sequence which is different from that of the BAC fragment having the sequence disclosed in SEQ ID NO:B (see Table IB, column 5).
  • polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table IB which correspond to the same Clone ID NO:Z (see Table IB, column 1) and have a nucleic acid sequence which is different from that published for the BAC clone identified as BAC ID NO:A (see Table IB, column 4).
  • the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table IB which corcespond to the same Clone ID NO:Z (see Table IB, column 1) and have a nucleic acid sequence which is different from that contained in the BAC clone identified as BAC ID NO:A (see Table IB, column 4).
  • Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides and polypeptides are also encompassed by the invention.
  • polynucleotides ofthe invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more ofthe sequences delineated in column 6 of Table IB which correspond to the same contig sequence identifer SEQ ID NO:X (see Table IB, column 2), or any combination thereof.
  • polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more ofthe complementary strand(s) of the sequences delineated in column 6 of Table IB which correspond to the same contig sequence identifer SEQ ID NO:X (see Table IB, column 2), or any combination thereof, h further embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table IB which correspond to the same contig sequence identifer SEQ ID NO:X (see Table IB, column 2) and have a nucleic acid sequence which is different from that of the BAC fragment having the sequence disclosed in SEQ ID NO:B (see Table IB, column 5).
  • the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table IB which correspond to the same contig sequence identifer SEQ ID NO:X (see Table IB, column 2) and have a nucleic acid sequence which is different from that published for the BAC clone identified as BAC ID NO:A (see Table IB, column 4).
  • the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table IB which correspond to the same contig sequence identifer SEQ ID NO:X (see Table IB, column 2) and have a nucleic acid sequence which is different from that contained in the BAC clone identified as BAC ID NO:A (See Table IB, column 4).
  • Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants ofthe above-described polynucleotides and polypeptides are also encompassed by the invention.
  • representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in the same row of Table IB column 6, or any combination thereof.
  • Additional, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the complementary strand(s) of the sequences delineated in the same row of Table IB column 6, or any combination thereof.
  • the polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the complementary strand(s) of the sequences delineated in the same row of Table IB column 6, wherein sequentially delineated sequences in the table (i.e. corresponding to those exons located closest to each other) are directly contiguous in a 5' to 3 ' orientation.
  • above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in the same row of Table IB, column 6, and have a nucleic acid sequence which is different from that of the BAC fragment having the sequence disclosed in SEQ ID NO:B (see Table IB, column 5).
  • the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in the same row of Table IB, column 6, and have a nucleic acid sequence which is different from that published for the BAC clone identified as BAC ID NO:A (see Table IB, column 4).
  • polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in the same row of Table IB, column 6, and have a nucleic acid sequence which is different from that contained in the BAC clone identified as BAC ID NO:A (see Table IB, column 4).
  • Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.
  • polynucleotides ofthe invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more ofthe sequences delineated in column 6 of Table IB, and the polynucleotide sequence of SEQ ID NO:X (e.g., as defined in Table IB, column 2) or fragments or variants thereof.
  • Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind. these polypeptides are also encompassed by the invention.
  • polynucleotides ofthe invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more ofthe sequences delineated in column 6 of Table IB which correspond to the same Clone ID NO:Z (see Table IB, column 1), and the polynucleotide sequence of SEQ ID NO:X (e.g., as defined in Table 1 A or IB) or fragments or variants thereof.
  • the delineated sequence(s) and polynucleotide sequence of SEQ .ID NO:X correspond to the same Clone ID NO:Z.
  • Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.
  • polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more ofthe sequences delineated in the same row of column 6 of Table IB, and the polynucleotide sequence of SEQ ID NO:X (e.g., as defined in Table IA or IB) or fragments or variants thereof, hi preferred embodiments, the delineated sequence(s) and polynucleotide sequence of SEQ ID NO:X correspond to the same row of column 6 of Table IB.
  • polynucleotides ofthe invention comprise, or alternatively consist of a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table IB and the 5' 10 polynucleotides of the sequence of SEQ ID NO:X are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention.
  • Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.
  • polynucleotides ofthe invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides of one ofthe sequences delineated in column 6 of Table IB and the 5' 10 polynucleotides of a fragment or variant of the sequence of SEQ ID NO:X are directly contiguous Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention.
  • Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.
  • polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides ofthe sequence of SEQ ID NO:X and the 5' 10 polynucleotides of the sequence of one of the sequences delineated in column 6 of Table IB are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention.
  • Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.
  • polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides of a fragment or variant of the sequence of SEQ ID NO:X and the 5' 10 polynucleotides of the sequence of one of the sequences delineated in column 6 of Table IB are directly contiguous.
  • Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention.
  • Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants ofthe above-described polynucleotides, nucleic acids, and polypeptides, are also encompassed by the invention.
  • polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table IB and the 5' 10 polynucleotides of another sequence in column 6 are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention.
  • Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.
  • polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table IB and the 5' 10 polynucleotides of another sequence in column 6 conesponding to the same Clone ID NO:Z (see Table IB, column 1) are directly contiguous. Nucleic acids which hybridize to the complement of these 20 lower stringency conditions, are also encompassed by the invention.
  • Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants ofthe above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.
  • polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides of one sequence in column 6 corresponding to the same contig sequence identifer SEQ ID NO:X (see Table IB, column 2) are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention.
  • Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.
  • polynucleotides of the invention comprise, or alternatively consist of a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table IB and the 5' 10 polynucleotides of another sequence in column 6 corresponding to the same row are directly contiguous.
  • the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table IB is directly contiguous with the 5' 10 polynucleotides of the next sequential exon delineated in Table IB, column 6.
  • Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions are also encompassed by the invention.
  • Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.
  • each contig sequence (SEQ ID NO:X) listed in the fourth column of Table IA preferably excluded are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 and the final nucleotide minus 15 of SEQ ID NO:X, b is an integer of 15 to the final nucleotide of SEQ ID NO:X, where both a and b conespond to the positions of nucleotide residues shown in SEQ ID NO:X, and where b is greater than or equal to a + 14.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a and b are integers as defined in columns 4 and 5, respectively, of Table 3.
  • the polynucleotides of the invention do not consist of at least one, two, three, four, five, ten, or more of the specific polynucleotide sequences referenced by the Genbank Accession No. as disclosed in column 6 of Table 3 (including for example, published sequence in connection with a particular BAC clone).
  • preferably excluded from the invention are the specific polynucleotide sequence(s) contained in the clones conesponding to at least one, two, three, four, five, ten, or more of the available material having the accession numbers identified in the sixth column of this Table (including for example, the actual sequence contained in an identified BAC clone). In no way is this listing meant to encompass all ofthe sequences which may be excluded by the general formula, it is just a representative example. All references available through these accessions are hereby incorporated by reference in their entirety. TABLE 3
  • HADTU18 26 666268 1 - 450 15 - 464 AAl 15399, AA180941, AI525779, AL048467, Z98468, AAl 80879, AL037961, AI132950, C18849, AI540982, AA503155, AA467916, AW270568, AA147875, AA523369, AA147138, C17914, AA248428, AA828615, AA610797, C17592, AA533146, AA468916, C17634, AA641056, AAl 82403, AA469384, AA131426, AA177092, AI535678, AL038782, AA548209, AI832713, AA181413, AI133326, C17520, AA533654, AA467874, AA468090, AA134092, AA469455, AA083296, AA214681, AI525553, AA1944
  • HNTEF53 27 954852 1 - 2342 15 - 2356 AA557324, AI655577, AI696732, AI923200, AA863360, AW262723, AI697332, AW275990, AI436648, AW276183, R56515, AI362521, R53456, R53457, D62878, AA337301, AA652746, AW264444, R56123, AA319338, D79346, D79250, N56346, AA886832, and ALl 38223.
  • HSDIL35 40 1228138 1-300 15-314 R45895, R28735, R29445, AA585325, AA585098, R29657, T18597, R28892, AA170832, R29218, AA585476, AA585101, D57491, AA283326, D60844, D61185, R28895, R28967, AA585439, C16315, Z32822, D60765, AI557734, D61254, Z28355, AI557262, D53161, AI546875, D59436, D53472, AI557864, AI541356, AI557740, R28965, D59751, AI547250, C15406, D54897, AI546945, AI526140, AI546971, AI541365, AI525500, AI525306, AA585155, AI546999, AI541383, AI541374, AI557763, C16293, C16294, Z32887, D
  • HAHHE43 44 1172244 1 - 2529 15 - 2543 AA442414, AL037261, AW070401, ' AI457525, AI016211, AI433014, AI240432, C21505, AW382682, AA587446, AA848047, AW074687, N38806, AI285709, AA024410, AI809829, AA551399, AA226173, AC006441, ALl 17258, AC005015, U91323, L78833, Z98200, AC004531, AC007225, AC002302, AC002420, AC005911, AP000557, AL031685, AC007637, AC005088, AC004883, AC005666, AC007277, AC005488, AL049761, AF001549, AC005089, AC004966, AC005037, AL023807, AF134726, AL031311, AC006064
  • HCHMV63 54 1190101 1 - 1439 15 - 1453 AA528091, AI937130, AL043928, AA512928, AI003767, AI950845, AI681293, AW020408, AI126197, AW189101, AA421192, N56993, AI081289, AI498013, AA278851, W76552, AA285337, AI568488, W74357, AA609588, AI634849, AA417379, AI272841, AI082525, H72715, AA862669, AA370112, F37679, R48578, AA508735, R18652, AA993015, R09304, T73701, AI383524, AW193459, AW027819, AA508168, AA298483, AA428290, AI608919, AI916400, AA360685, AI001776, AW189612, R09199, AI
  • HCWDL45 55 889416 1 - 397 15 - 411 Z98747, AC023100, and Z98747.
  • HDDAF49 58 1125713 1 - 906 15 - 920 AL133047.
  • HDPGS68 60 752975 1 - 448 15 - 462 AC034180.
  • HDPIX67 61 1172240 1 - 2934 15 - 2948 AF147773, AF152898, AI708697, N51342, AA825888, AI292226, AI288960, N39421, AA975060, AI261689, AW291891, N48537, AI695627, AA406030, AI699867, AA406029, H26638, AL046205, AA669840, AL046409, AI284640, AW274346, AA508359, AW069510, AW303196, AI963720, AI431303, AW301350, AA490183, AI270117, AW079792, AI583283, AW193265, AW274349, AI799642, AA468244, AI370878, AI654525, AA584195, AA806796, AA846876, AL138455, AI434695, AA587604, AI972203, AW
  • HDPXN01 62 1125610 1 - 495 15 - 509 AI651231, AW196757, AA101088, AI627422, W94251, W94274, AA912880, AI093809, AI867562, H06521, H20526, AW151979, AI590043, AI554821, AW151136, AI539771, AI537677, AI494201, AI500659, AI828574, AI866465, AI815232, AI801325, AI500523, AI538850, AI887775, AI582932, AI872423, AI284517, AI923989, AI500706, AI491776, AI445237, AW151138, AI521560, AI889189, AI500662, AI539800, AW172723, AI284509, AI538885, AI889168, AI440263, AI866573, AI633493, AI434256, AI866469, AI434242, AI805769
  • HEFMB30 68 691516 1 - 403 15 - 417 AI813271, AI459195, AI796347, T71268, AA702812, AC012481, AC012481, AC016659, and AC016659.
  • HETBR74 70 948667 1 - 863 15 - 877 AI424957, AA865175, AI345105, AW337653, AI493383, AA992117, W86236, AW001913, T23935, AI141791, AI277560, T33653, T91218, AA469060, AA148613, AI635951, AI500569, T72018, AI290957, AA159337, T32385, AI088662, AI140973, AA534837, F10818, AI703234, AA486780, AI935264, AA999981, T94771, H50506, AA774208, T98781, H51340, H43580, N57875, AI696236, H44933, N64109, N40952, and AL137633.
  • HFCAG94 71 1111177 1 - 997 15 - 1011 AA338681, AI457313, AI634187, AW069227, AI978782, AL079734, AA021561, AWl 17704, AW083102, AW117723, AI432298, AI431513, AI889579, AA176605, AI004591, AI653776, AA629412, F24745, AA219349, AA056250, H29914, AI469599, AW082104, AI912401, AI206841, AI962030, F35684, AA583386, AA130647, AI189682, AW002831, AW272774, AI355246, AW302017, AW130591, AI280266, AI491765, H53284, AA773463, R93919, T47138, AI583291, AI434037, AA493110, AA452887, AI360514, F
  • HFPHR82 72 957528 1 - 1579 15 - 1593 AA913364, AW027373, AW305275, AI799031, AW117480, AA588138, AA775450, AW190848, AA411334, AA866178, W61038, AA411335, AA775769, AA769134, AA075643, N30274, AI493881, AA627544, AI147666, AA075644, AA614747, N30309, AA812101, AI025647, AW339918, AI140386, N94919, AI138196, AA868924, AI143201, AA284960, AI347094, AI343592, AI128292, AI017993, AI492556, N41996, N20511, N42630, AI933338, AI554835, W72001, W69402, AI679099, AA040263, T32745, AA872581
  • HSDFT51 86 1124582 1 - 1355 15 - 1369 AI422221, AW269213, T11456, H84186, AI142300, AI348147, AA705920, AI657002, AW028877, AA928672, AI587025, W03281, AI765590, AI954911, AI936593, AI355533, AI244341, AW173240, AI797712, AI219155, AW303951, AI696467, AI148012, H53272, C06193, AC004874, U91321, AC004804, AP001067, AC004106, Z99291, AC003087, AC004887, AC008149, AL133249, AP001068, AJ011930, AL021921, AL023586, U95738, AL022578, AL031056, AP000966, AL133238, AC006390, AC004551, AC005186, AL008733, AC00
  • HSODC08 91 966264 1 - 1432 15 - 1446 AW007193, N64811, AA452032, AW339062, AW340188, AA401432, AI568619, AW169936, AI680519, AI271472, AA131132, AA400000, AA885882, AI338757, H94846, AA749092, AA406402, AA771971, AI250802, AI499729, W95739, AA975465, AI147856, AI521267, W95717, AA284462, AA902995, AI969258, AI143369, AA668710, AA772776, AA410424, AI278748, AA465528, AI094421, AI280111, AI031849, AI022538, H94904, AA448926, AA932880, AA939066, N50516, AI026050, AA888455, W46552,
  • HWBBR65 98 1156447 1 - 2238 15 - 2252 All 10760, AL040921, AL048969, AL044339, AL044340, AI608771, AW188427, AW102811, AL037632, AI054414, AW157180, AL138265, AI952885, AI302688, AL048626, AL044489, AW080062, AA223932, AA126635, AL042906, AI791227, ALl 19331, AI076616, AL042905, AW408643, AI354847, AW243793, AL135377, AI679294, AA134961, AI679871, .AA601278, AI732911, AW069819, AI694178, AA487475, AI457389, AI907046, H57596, AI961264, AA736713, AL041013, AI871691, AI816537, AA287618, AA020873, AL13
  • HBCBT19 112 959953 1 - 758 15 - 772 W58728, AW194384, AI921843, AA131986, W27452, AA861776, AW025219, AA366467, AA969204, AI077983, AI688167, AA805925, AI939498, T82046, AA026664, AI627470, R71811, AW316534, All 89664, R60094, AA007217, R53357, AA335794, AI401269, AI024367, AA131681, AA505874, AI200318, R71771, W24578, AA026712, AI676036, AA806045, AI299373, AI890667, AWl 18903, H29874, N92383, H92161, AI267768, AW075217, AA918168, AI885357, AW372475, AW172330, AA844743,
  • HBCPT10 113 957631 1 - 1278 15 - 1292 AI131178, AI073401, AI087304, AW001150, AI870504, AA632131, AA527353, AI268314, AI199367, AI279189, AW419191, AA293161, AA639837, AI859436, AA777588, AI936230, AW071823, AA809698, AA528107, W72175, AA719229, AA809330, AI333884, AI138637, AI202785, N33080, AI299098, AA527330, AI826773, AI026030, AI291245, AA782731, AA932449, W51877, AA429946, AA931756, W76461, AA135492, AA714047, AA977092, AA293652, AW245862, AA890559, AA306873, AA
  • HBGDA14 114 866258 1 - 879 15 - 893 AC024580, and AC074220.
  • HSLEI57 140 1103672 1 - 627 15 - 641 AW177501, AW177511, AW177440, AI905856, AW366296, AW178893, AW375405, D51097, AW377671, T03269, C14389, AW179328, D58283, D59859, D80022, C14331, D80166, D80195, D80193, D59927, D59467, D51423, D59619, D80210, D51799, D80391, D80164, D59275, D80240, D80253, D80043, D59787, D80227, D59502, AA305409, AW378532, AA305578, AW360811, D80248, AA514188, D80132, D81030, D80269, D80212, D80366, D80196, D80188, D80219, D80134, D80038, C15076
  • HTXHA35 143 1152110 1 - 924 15 - 938 AI707816, AI523073, AA150070, AA393871, R48107, AW002940, AA449214, AA372202, R05612, AA310756, R52299, AA361396, AA425098, R77016, AF151821, and AB015724.
  • HBKDN33 145 1167313 1 - 1001 15 - 1015 AA099783, H54765, H56600, R21717, AA464329, W69565, W72942, N73344, N73216, R20503, .AA285107, H96024, AA284952, AA131052, AF216873, and AL049709.
  • HEEAA32 150 1203140 1 - 1920 15 - 1934 AI733019, AI821967, AI401824, AI305817, AI248775, AI791417, N63067, AA769662, AI636297, AI436700, AI373787, AI279773, AI823325, AI913400, AI431755, AW271322, AA873330, AW006890, AI433320, AW027962, and AW772149.
  • HEGAN70 151 839719 1 - 891 15 - 905 AA995279, .M78884, and AB023151.
  • HFKMF42 152 1104119 1 - 1544 15 - 1558 AW025904, AW008529, AI680826, AI743467, AI083911, AI950071, AI015927, AA805175, AA251134, AA310596, AA603773, AA516361, F08785, AA953720, AI701937, .AA852503, AA687875, AI873898, AA251198, AA742963, AI087970, Z41828, AA931078, AW131728, AW204102, AW244102, AA948773, AA283246, AI929279, AW081255, AI473598, AI468872, AI699011, AI866608, AI758528, AW088899, AI273843, AI446373, AI343059, AI349933, AI932638, AI345608, AW089179, AW088903, AI49
  • HHEMB89 154 1227613 1 - 3551 15 - 3565 AW007194, AW170529, AI569739, AI684951, AW408053, AW262667, AA936961, AW129510, AW024994, AI161063, AI356425, AI565468, AI762466, All 93147, AI198432, AI148726, AI168487, AI086481, AW089488, AW024920, N67766, AI333983, AI333014, AW025667, AI983417, AI018650, AA811890, AA993603, AI202461, AA580377, N62890, AI300259, AI161057, AA393307, W03611, .AI478819, AI241110, AA469272, AW403243, N77799, F24483, AI499835, AA469350, H64730, AA398596
  • HBCMD49 175 1206021 1 - 907 15 - 921 AI190179, AA632398, AI452983, AA436085, AA974047, AA746327, AA856609, AA379426, AA954235, AI015697, AA435985, AA379438, AI561289, F17297, and T53860.
  • HISCL24 182 676997 1 - 574 15 - 588 AW294538, W23746, AI078278, E15871, E15865, E15866, AB016789, and AB016780.
  • H7PBB83 183 1228150 1 - 1350 15 - 1364 AI866480, AI983534, AI274967, AI333019, AW303755, AW452025, N31757, N31555, AA496999, AA161418, AL040482, AA630664, N39479, AA648068, All 14875, 68311, 51330, H95917, AA648602, AA308992, F37190, AA403243, AA830558, AA262117, N98795, AA186599, F28863, N57116, AA595742, AI913895, AC007450, L39119, Y11107, D44443, AR038762, AJ005168, AJ245869, U67221, AF054142, and AF019721.
  • HCRPZ84 186 1130816 1 - 1953 15 - 1967 Z20545, AA099688, AI718277, AI535926, AI806204, AI922705, AWl 89584, Z20083, AA134958, AW152541, AC007750, 150897, A74554, and A74468.
  • HCW1R54 187 1192287 1 - 370 15 - 384 AI302350, AW275432, AI249688, AA458534, AA593471, AA610255, AW167154, AI002261, AI590476, 194116, AA569202, AI598003, AI832865, F36273, AA516207, AA664604, AA347927, AA579278, AA548029, AW166611, AL039187, AA346586, AI962050, AA508809, AA347930, AI284640, AI340832, AW021917, AI014378, AI863399, AA627154, AA728937, H96518, AA347114, AI244356, AA843450, AI305258, AI859280, AA167741, AA350859, AL133950, AA574353, AA862243, AI613465, AA804925
  • HDPBB41 1195686 1 - 2874 15 - 2888 AA629318, AI760806, AA206978, AL043066, AW166212, AA425460, AI827760, AI797084, AA320491, AI127411, AI817660, AI004566, C02558, AA810594, AA703440, AI497709, AI435494, AI702289, AA460950, AI940414, 197071, 191922, 107472, AL122076, AF082179, AF173643, and AF088884.
  • HOGAQ10 200 1222600 1 - 2476 15 - 2490 AI653115, AI281473, AI377912, AA815186, AI280027, AA491250, AA197295, W24286, N95450, AI825293, AA832432, AA628231, W25169, N93682, D59275, C14389, D80164, D80195, D59467, D80227, D59502, D58283, D50979, D59859, D80022, D80166, D80043, C15076, D51423, D59619, C14331, D80210, D51799, D80391, D80240, D80253, D59787, D81030, D80269, D59610, D80038, D80193, D80188, D80212, D80196, AA305409, D80219, D59927, D57483, D80378, D80366, AA305578, D
  • HOSBW20 201 985056 1 - 913 15 - 927 H08004, R24580, AA291098, Z42372, and AA625285.
  • EIAMFW05 230 957586 1 - 1034 15 - 1048 AC005594, AC005594, and AC005594.
  • HOVC014 244 947999 1 - 580 15 - 594 AI701529, AA994711, AI192036, and AC007198.
  • HTOBE75 245 1161571 1 - 1840 15 - 1854 AW192827, AA595431, AI251121, AI923335, AI284016, H30141, 170540, T90549, AI432106, AA953436, H27466, R50714, R50249, AI540363, 170809, AI659868, AW370667, AI678688, AI802240, AW004886, AW080379, AI352274, AI254727, AI537677, AI917963, AI491710, AW163823, AI569328, AI249962, AI570966, AI919593, AW088903, AW151714, AW129230, AI539771, AI873638, AI434242, AI801793, AI697324, AI589428, AW162194, AI888621, AI918449, AI587121, AW168451, AW089006, AI812015, AI
  • HBMUJ35 261 1195500 1 - 2104 15 - 2118 AI076933, AA528171, AI401590, AI718291, AI689866, AI863198, AW131778, AI038040, AI147972, AI249927, AI365611, AI288899, AI151170, AA700233, H17877, AI954954, AW162862, AI540170, D61629, H17876, AI198286, AW044526, H42874, AI139301, AI242217, Z39310, W79945, AI075889, AA243131, R56563, AA535601, AI741349, AA810355, AA279039, H42938, R75964, AF141289, U72621, X06146, AF039202, ALl 10158, AFl 18847, AF145233, AF129131, A49723, A49722, AF139373, E06743,
  • HWBDP39 270 1223498 1 - 3163 15 - 3177 AI830320, AI650699, AA425859, AL135164, AW407213, R93643, 108247, AA903976, AI339150, AA393578, D81801, AA069108, H05354, 178715, H17603, AW375579, AA425265, H14868, AA353380, AA382228, 131679, H28195, AI452888, H60758, AW341054, H21724, R44576, H05304, R19312, H28238, AA344135, W24078, R60163, AA397778, AA804197, R47192, R47367, 170745, AA350456, N72648, W03235, N56575, N87382, R72018, R07516, R46310, R73289, R46877, H43991, R9449

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne de nouvelles protéines. Plus spécifiquement, l'invention concerne des molécules d'acides nucléiques isolées codant de nouveaux polypeptides. L'invention concerne également des nouveaux polypeptides et des anticorps se fixant à ces polypeptides. De plus, l'invention concerne des vecteurs, des cellules hôtes ainsi que des méthodes de recombinaison et de synthèse permettant la production de polynucléotides et/ou polypeptides ainsi que des anticorps humains. L'invention concerne aussi des méthodes diagnostiques et thérapeutiques utiles pour diagnostiquer, traiter, prévenir et/ou pronostiquer des troubles liés à ces nouveaux polypeptides. L'invention concerne aussi des méthodes de criblage permettant d'identifier des agonistes et des antagonistes de polynucléotides et de polypeptides de l'invention. En outre l'invention concerne des méthodes et/ou des compositions destinées à inhiber ou à augmenter la production et la fonction des polypeptides de la présente invention.
PCT/US2001/001239 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps WO2001055301A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2001252878A AU2001252878A1 (en) 2000-01-31 2001-01-17 Nucleic acids, proteins, and antibodies
AU5287801A AU5287801A (en) 2000-01-31 2001-01-29 Nucleic acids, proteins, and antibodies
US09/908,711 US20020045230A1 (en) 2000-08-14 2001-07-20 Nucleic acids, proteins, and antibodies

Applications Claiming Priority (235)

Application Number Priority Date Filing Date Title
US17906500P 2000-01-31 2000-01-31
US60/179,065 2000-01-31
US18062800P 2000-02-04 2000-02-04
US60/180,628 2000-02-04
US18466400P 2000-02-24 2000-02-24
US60/184,664 2000-02-24
US18635000P 2000-03-02 2000-03-02
US60/186,350 2000-03-02
US18987400P 2000-03-16 2000-03-16
US60/189,874 2000-03-16
US19007600P 2000-03-17 2000-03-17
US60/190,076 2000-03-17
US19812300P 2000-04-18 2000-04-18
US60/198,123 2000-04-18
US20551500P 2000-05-19 2000-05-19
US60/205,515 2000-05-19
US20946700P 2000-06-07 2000-06-07
US60/209,467 2000-06-07
US21488600P 2000-06-28 2000-06-28
US60/214,886 2000-06-28
US21513500P 2000-06-30 2000-06-30
US60/215,135 2000-06-30
US21688000P 2000-07-07 2000-07-07
US21664700P 2000-07-07 2000-07-07
US60/216,880 2000-07-07
US60/216,647 2000-07-07
US21749600P 2000-07-11 2000-07-11
US21748700P 2000-07-11 2000-07-11
US60/217,487 2000-07-11
US60/217,496 2000-07-11
US21829000P 2000-07-14 2000-07-14
US60/218,290 2000-07-14
US22096400P 2000-07-26 2000-07-26
US22096300P 2000-07-26 2000-07-26
US60/220,963 2000-07-26
US60/220,964 2000-07-26
US22575700P 2000-08-14 2000-08-14
US22451800P 2000-08-14 2000-08-14
US22575800P 2000-08-14 2000-08-14
US22451900P 2000-08-14 2000-08-14
US22526700P 2000-08-14 2000-08-14
US22527000P 2000-08-14 2000-08-14
US22521400P 2000-08-14 2000-08-14
US22575900P 2000-08-14 2000-08-14
US22544700P 2000-08-14 2000-08-14
US22521300P 2000-08-14 2000-08-14
US22526600P 2000-08-14 2000-08-14
US22526800P 2000-08-14 2000-08-14
US60/225,267 2000-08-14
US60/225,213 2000-08-14
US60/225,268 2000-08-14
US60/224,518 2000-08-14
US60/225,266 2000-08-14
US60/225,447 2000-08-14
US60/224,519 2000-08-14
US60/225,270 2000-08-14
US60/225,759 2000-08-14
US60/225,214 2000-08-14
US60/225,758 2000-08-14
US60/225,757 2000-08-14
US22627900P 2000-08-18 2000-08-18
US60/226,279 2000-08-18
US22686800P 2000-08-22 2000-08-22
US22718200P 2000-08-22 2000-08-22
US22668100P 2000-08-22 2000-08-22
US60/226,681 2000-08-22
US60/227,182 2000-08-22
US60/226,868 2000-08-22
US22700900P 2000-08-23 2000-08-23
US60/227,009 2000-08-23
US22892400P 2000-08-30 2000-08-30
US60/228,924 2000-08-30
US22934300P 2000-09-01 2000-09-01
US22928700P 2000-09-01 2000-09-01
US22934500P 2000-09-01 2000-09-01
US22934400P 2000-09-01 2000-09-01
US60/229,287 2000-09-01
US60/229,343 2000-09-01
US60/229,345 2000-09-01
US60/229,344 2000-09-01
US22951300P 2000-09-05 2000-09-05
US22950900P 2000-09-05 2000-09-05
US60/229,513 2000-09-05
US60/229,509 2000-09-05
US23043700P 2000-09-06 2000-09-06
US23043800P 2000-09-06 2000-09-06
US60/230,437 2000-09-06
US60/230,438 2000-09-06
US23124400P 2000-09-08 2000-09-08
US23124300P 2000-09-08 2000-09-08
US23141300P 2000-09-08 2000-09-08
US23124200P 2000-09-08 2000-09-08
US23208100P 2000-09-08 2000-09-08
US23208000P 2000-09-08 2000-09-08
US23141400P 2000-09-08 2000-09-08
US60/231,244 2000-09-08
US60/231,413 2000-09-08
US60/232,080 2000-09-08
US60/231,414 2000-09-08
US60/231,242 2000-09-08
US60/231,243 2000-09-08
US60/232,081 2000-09-08
US23196800P 2000-09-12 2000-09-12
US60/231,968 2000-09-12
US23239700P 2000-09-14 2000-09-14
US23240000P 2000-09-14 2000-09-14
US23240100P 2000-09-14 2000-09-14
US23239800P 2000-09-14 2000-09-14
US23306500P 2000-09-14 2000-09-14
US23306400P 2000-09-14 2000-09-14
US23306300P 2000-09-14 2000-09-14
US23239900P 2000-09-14 2000-09-14
US60/232,400 2000-09-14
US60/233,064 2000-09-14
US60/232,397 2000-09-14
US60/232,401 2000-09-14
US60/232,399 2000-09-14
US60/232,398 2000-09-14
US60/233,065 2000-09-14
US60/233,063 2000-09-14
US23427400P 2000-09-21 2000-09-21
US23422300P 2000-09-21 2000-09-21
US60/234,223 2000-09-21
US60/234,274 2000-09-21
US23499700P 2000-09-25 2000-09-25
US23499800P 2000-09-25 2000-09-25
US60/234,998 2000-09-25
US60/234,997 2000-09-25
US23548400P 2000-09-26 2000-09-26
US60/235,484 2000-09-26
US23583600P 2000-09-27 2000-09-27
US23583400P 2000-09-27 2000-09-27
US60/235,836 2000-09-27
US60/235,834 2000-09-27
US23636700P 2000-09-29 2000-09-29
US23636800P 2000-09-29 2000-09-29
US23637000P 2000-09-29 2000-09-29
US23632700P 2000-09-29 2000-09-29
US23636900P 2000-09-29 2000-09-29
US60/236,367 2000-09-29
US60/236,327 2000-09-29
US60/236,368 2000-09-29
US60/236,370 2000-09-29
US60/236,369 2000-09-29
US23703800P 2000-10-02 2000-10-02
US23680200P 2000-10-02 2000-10-02
US23703700P 2000-10-02 2000-10-02
US23704000P 2000-10-02 2000-10-02
US23703900P 2000-10-02 2000-10-02
US60/237,038 2000-10-02
US60/237,040 2000-10-02
US60/237,037 2000-10-02
US60/237,039 2000-10-02
US60/236,802 2000-10-02
US23993500P 2000-10-13 2000-10-13
US23993700P 2000-10-13 2000-10-13
US60/239,937 2000-10-13
US60/239,935 2000-10-13
US24122100P 2000-10-20 2000-10-20
US24182600P 2000-10-20 2000-10-20
US24180900P 2000-10-20 2000-10-20
US24178500P 2000-10-20 2000-10-20
US24180800P 2000-10-20 2000-10-20
US24178700P 2000-10-20 2000-10-20
US24178600P 2000-10-20 2000-10-20
US24096000P 2000-10-20 2000-10-20
US60/241,809 2000-10-20
US60/241,786 2000-10-20
US60/241,808 2000-10-20
US60/241,826 2000-10-20
US60/241,785 2000-10-20
US60/241,221 2000-10-20
US60/240,960 2000-10-20
US60/241,787 2000-10-20
US24461700P 2000-11-01 2000-11-01
US60/244,617 2000-11-01
US24652600P 2000-11-08 2000-11-08
US24652500P 2000-11-08 2000-11-08
US24652700P 2000-11-08 2000-11-08
US24647600P 2000-11-08 2000-11-08
US24661100P 2000-11-08 2000-11-08
US24647500P 2000-11-08 2000-11-08
US24647400P 2000-11-08 2000-11-08
US24652800P 2000-11-08 2000-11-08
US24647700P 2000-11-08 2000-11-08
US24661000P 2000-11-08 2000-11-08
US24653200P 2000-11-08 2000-11-08
US60/246,525 2000-11-08
US60/246,475 2000-11-08
US60/246,526 2000-11-08
US60/246,609 2000-11-08
US60/246,474 2000-11-08
US60/246,611 2000-11-08
US60/246,527 2000-11-08
US60/246,613 2000-11-08
US60/246,478 2000-11-08
US60/246,477 2000-11-08
US60/246,476 2000-11-08
US60/246,532 2000-11-08
US60/246,528 2000-11-08
US60/246,610 2000-11-08
US60/246,524 2000-11-08
US60/246,523 2000-11-08
US60/249,211 2000-11-17
US60/249,244 2000-11-17
US60/249,212 2000-11-17
US60/249,214 2000-11-17
US60/249,265 2000-11-17
US60/249,213 2000-11-17
US60/249,217 2000-11-17
US60/249,264 2000-11-17
US60/249,216 2000-11-17
US60/249,208 2000-11-17
US60/249,245 2000-11-17
US60/249,207 2000-11-17
US60/249,300 2000-11-17
US60/249,299 2000-11-17
US60/249,218 2000-11-17
US60/249,215 2000-11-17
US60/249,297 2000-11-17
US60/249,209 2000-11-17
US60/249,210 2000-11-17
US60/250,160 2000-12-01
US60/250,391 2000-12-01
US60/251,988 2000-12-05
US60/251,030 2000-12-05
US60/256,719 2000-12-05
US60/251,479 2000-12-06
US60/251,869 2000-12-08
US60/251,856 2000-12-08
US60/251,990 2000-12-08
US60/251,989 2000-12-08
US60/251,868 2000-12-08
US60/254,097 2000-12-11
US60/259,678 2001-01-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/908,711 Continuation-In-Part US20020045230A1 (en) 2000-08-14 2001-07-20 Nucleic acids, proteins, and antibodies

Publications (3)

Publication Number Publication Date
WO2001055301A2 true WO2001055301A2 (fr) 2001-08-02
WO2001055301A8 WO2001055301A8 (fr) 2001-09-07
WO2001055301A3 WO2001055301A3 (fr) 2009-06-04

Family

ID=27587117

Family Applications (48)

Application Number Title Priority Date Filing Date
PCT/US2001/001351 WO2001055355A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001340 WO2001055321A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001309 WO2001055308A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001333 WO2001055448A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001348 WO2001055368A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001343 WO2001055323A2 (fr) 2000-01-31 2001-01-17 Acides ncleiques, proteines et anticorps
PCT/US2001/001355 WO2001055207A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001322 WO2001055343A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001327 WO2001055203A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001312 WO2001054733A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001314 WO2001055310A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001326 WO2001055315A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines, et anticorps
PCT/US2001/001316 WO2001054473A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001325 WO2001055202A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001359 WO2001055328A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001301 WO2001055303A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001302 WO2001055304A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001240 WO2001055302A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001353 WO2001055206A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001352 WO2001055327A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001356 WO2001055173A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001349 WO2001054474A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001338 WO2001055367A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et antigenes
PCT/US2001/001335 WO2001055319A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001344 WO2001055324A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001315 WO2001055311A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001317 WO2001055201A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001306 WO2001055307A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001336 WO2001055204A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001313 WO2001055200A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001332 WO2001055318A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001357 WO2001055208A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001342 WO2001059064A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001311 WO2001055309A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001358 WO2001055163A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines, et anticorps
PCT/US2001/001330 WO2001055447A1 (fr) 2000-01-31 2001-01-17 Acides nucléiques, proteines et anticorps
PCT/US2001/001354 WO2001057182A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001310 WO2001055387A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001321 WO2001055312A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001308 WO2001055364A2 (fr) 2000-01-31 2001-01-17 Acides nucléiques, protéines et anticorps
PCT/US2001/001341 WO2001055322A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001239 WO2001055301A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001328 WO2001055316A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001350 WO2001055350A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001324 WO2001055314A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001337 WO2001055205A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001345 WO2001055325A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001339 WO2001055320A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps

Family Applications Before (41)

Application Number Title Priority Date Filing Date
PCT/US2001/001351 WO2001055355A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001340 WO2001055321A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001309 WO2001055308A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001333 WO2001055448A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001348 WO2001055368A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001343 WO2001055323A2 (fr) 2000-01-31 2001-01-17 Acides ncleiques, proteines et anticorps
PCT/US2001/001355 WO2001055207A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001322 WO2001055343A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001327 WO2001055203A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001312 WO2001054733A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001314 WO2001055310A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001326 WO2001055315A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines, et anticorps
PCT/US2001/001316 WO2001054473A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001325 WO2001055202A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001359 WO2001055328A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001301 WO2001055303A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001302 WO2001055304A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001240 WO2001055302A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001353 WO2001055206A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001352 WO2001055327A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001356 WO2001055173A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001349 WO2001054474A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001338 WO2001055367A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et antigenes
PCT/US2001/001335 WO2001055319A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001344 WO2001055324A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001315 WO2001055311A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001317 WO2001055201A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001306 WO2001055307A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001336 WO2001055204A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001313 WO2001055200A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001332 WO2001055318A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001357 WO2001055208A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001342 WO2001059064A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001311 WO2001055309A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001358 WO2001055163A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines, et anticorps
PCT/US2001/001330 WO2001055447A1 (fr) 2000-01-31 2001-01-17 Acides nucléiques, proteines et anticorps
PCT/US2001/001354 WO2001057182A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001310 WO2001055387A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001321 WO2001055312A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001308 WO2001055364A2 (fr) 2000-01-31 2001-01-17 Acides nucléiques, protéines et anticorps
PCT/US2001/001341 WO2001055322A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps

Family Applications After (6)

Application Number Title Priority Date Filing Date
PCT/US2001/001328 WO2001055316A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001350 WO2001055350A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001324 WO2001055314A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001337 WO2001055205A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001345 WO2001055325A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001339 WO2001055320A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps

Country Status (3)

Country Link
AU (16) AU2001241409A1 (fr)
CA (37) CA2395666A1 (fr)
WO (48) WO2001055355A1 (fr)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081586A2 (fr) * 2000-04-26 2001-11-01 Millennium Pharmaceuticals, Inc. 21657, deshydrogenase humaine a chaine courte et ses utilisations
WO2001083754A2 (fr) * 2000-05-02 2001-11-08 Immusol, Incorporated Regulateurs cellulaires d'agents infectieux et methodes d'utilisations
WO2001096546A2 (fr) * 2000-06-16 2001-12-20 Incyte Genomics, Inc. Proteine-phosphatases
WO2001096542A2 (fr) * 2000-06-15 2001-12-20 Millennium Pharmaceuticals, Inc. 23680, nouvelle aminotransferase humaine et utilisations de celle-ci
WO2002000861A2 (fr) * 2000-06-26 2002-01-03 Millennium Pharmaceuticals, Inc. 46619, une nouvelle synthase beta-cetoacyle et utilisations de cette derniere
WO2002018582A2 (fr) * 2000-08-31 2002-03-07 Millennium Pharmaceuticals, Inc. 62112, nouvelle deshydrogenase humaine et ses utilisations
WO2002018552A2 (fr) * 2000-08-30 2002-03-07 Bayer Aktiengesellschaft Regulation d'enzyme humaine de type aminotransferase
WO2002020754A2 (fr) * 2000-09-05 2002-03-14 Incyte Genomics, Inc. Molecules utilisees a des fins diagnostiques et therapeutiques
WO2002036781A2 (fr) * 2000-10-31 2002-05-10 Bayer Aktiengesellschaft Regulation de la glutathione-s-transferase humaine
WO2002006453A3 (fr) * 2000-07-18 2002-12-05 Bayer Ag Regulation de protease a serine humaine de type desc1
WO2002022806A3 (fr) * 2000-09-14 2003-01-16 Pe Corp Ny Proteines de phospholipase humaines isolees, molecules d'acides nucleiques codant les proteines de phospholipase humaines et utilisations associees
WO2002031132A3 (fr) * 2000-10-11 2003-03-13 Millennium Pharm Inc Nouvel element de la famille des phosphatases humaines a double specificite, appele 8843, et utilisation de ce dernier
WO2003057870A1 (fr) * 2002-01-07 2003-07-17 Bayer Healthcare Ag Proteine humaine analogue a la phosphatase de l'acide phosphatidique de type 2
WO2003062429A1 (fr) * 2002-01-23 2003-07-31 Yamanouchi Pharmaceutical Co., Ltd. Nouvelle serine protease
WO2002034922A3 (fr) * 2000-10-20 2003-08-28 Pe Corp Ny Proteines humaines isolees metabolisant les medicaments, molecules d'acide nucleique codant les proteines humaines metabolisant les medicaments et utilisations correspondantes
WO2004009626A1 (fr) * 2002-07-22 2004-01-29 Yamanouchi Pharmaceutical Co., Ltd. Nouveau gene associe a l'arthrite rhumatoide
WO2005024055A1 (fr) * 2003-09-05 2005-03-17 Garvan Institute Of Medical Research Procedes de diagnostic et de pronostic du cancer ovarien ii
EP1623993A2 (fr) * 1999-09-01 2006-02-08 Genetech, Inc. Protéines sécrétées et transmembranaires et acides nucléiques les codant
US8334264B2 (en) 2008-07-24 2012-12-18 NsGenee A/S Therapeutic use of a growth factor, METRNL
US8404642B2 (en) 2010-10-01 2013-03-26 Nsgene A/S Treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
WO2013068445A1 (fr) * 2011-11-09 2013-05-16 Sanofi Diacylglycérol lipase et applications associées
US9474786B2 (en) 2011-09-05 2016-10-25 Nsgene A/S Treatment of allodynia
US9845344B2 (en) 2004-03-30 2017-12-19 Hoba Therapeutics Aps Therapeutic use of a growth factor, NsG33
EP3344776A4 (fr) * 2015-09-04 2019-09-04 Synthetic Genomics, Inc. Microorganismes modifiés pour améliorer la productivité

Families Citing this family (247)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008288A2 (fr) * 2000-07-20 2002-01-31 Genentech, Inc. Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7579160B2 (en) 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US6960570B2 (en) 1998-03-18 2005-11-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7258860B2 (en) 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6706262B1 (en) 1998-03-18 2004-03-16 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
CA2328496C (fr) 1998-05-15 2016-01-05 Genentech, Inc. Polypeptides homologues de il-17 et utilisations therapeutiques de ceux-ci
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US6929938B2 (en) 2001-08-15 2005-08-16 Millennium Pharmaceuticals, Inc. 25501, a human transferase family member and uses therefor
WO2000050565A2 (fr) * 1999-02-25 2000-08-31 Thomas Jefferson University Compositions, kits et procedes concernant le gene fez1 de l'homme, nouveau gene suppresseur des tumeurs
US7141417B1 (en) 1999-02-25 2006-11-28 Thomas Jefferson University Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene
EP1157038A4 (fr) * 1999-02-26 2005-01-19 Smithkline Beecham Corp Clonage du recepteur 7tm (axor 17) du type p2y
WO2000056881A1 (fr) * 1999-03-23 2000-09-28 Human Genome Sciences, Inc. 48 proteines humaines secretees
CA2365601A1 (fr) 1999-03-29 2000-10-05 Kansai Technology Licensing Organization Co., Ltd. Nouvelle cytidine desaminase
US20020151047A1 (en) * 2001-01-08 2002-10-17 Yi Hu Novel human protease and polynucleotides encoding the same
AU1238201A (en) * 1999-10-27 2001-05-08 Millennium Pharmaceuticals, Inc. Novel molecules and the card-related protein family and uses thereof
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
US7005499B1 (en) * 1999-11-18 2006-02-28 Genentech, Inc. Wnt-regulated cytokine-like polypeptide and nucleic acids encoding same
EP1878795A3 (fr) * 1999-11-30 2008-01-23 Genentech, Inc. Compositions et procédés pour le traitement de maladies liées au système immunitaire
EP1250426A2 (fr) * 1999-12-01 2002-10-23 Genentech Inc. Polypeptides transmembranaires et secretes et les acides nucleiques codant ceux-ci
CN1300781A (zh) * 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽-人shc蛋白43和编码这种多肽的多核苷酸
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
AU2001237973B2 (en) 2000-01-26 2006-09-07 Agensys, Inc. 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
US6953682B2 (en) 2000-02-10 2005-10-11 Millennium Pharmaceuticals, Inc. Nucleic acid sequences encoding adenylate kinase, phospholipid scramblase-like, DNA fragmentation factor-like, phosphatidylserine synthase-like, and atpase-like molecules and uses therefor
US7078205B2 (en) 2000-02-17 2006-07-18 Millennium Pharmaceuticals, Inc. Nucleic acid sequences encoding melanoma associated antigen molecules, aminotransferase molecules, atpase molecules, acyltransferase molecules, pyridoxal-phosphate dependent enzyme molecules and uses therefor
US20020082212A1 (en) * 2000-07-20 2002-06-27 Millennium Pharmaceuticals, Inc. 7716, a novel human ATPase and uses therefor
US20020090705A1 (en) * 2000-07-14 2002-07-11 Rachel Meyers 62088, a novel human nucleoside phosphatase family member and uses thereof
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
AU2001250980A1 (en) * 2000-03-23 2001-10-03 Carmela Beger Brca-1 regulators and methods of use
AU2001245974A1 (en) 2000-03-24 2001-10-08 Millennium Pharmaceuticals, Inc. 3714, 16742, 23546, and 13887 novel protein kinase molecules and uses therefor
US20030198953A1 (en) * 2000-03-30 2003-10-23 Spytek Kimberly A. Novel proteins and nucleic acids encoding same
US7632929B2 (en) 2000-04-20 2009-12-15 The Board Of Trustees Of The University Of Arkansas Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof
JP2004511205A (ja) 2000-04-25 2004-04-15 レキシコン・ジェネティクス・インコーポレーテッド 新規ヒトキナーゼプロテインおよびそれをコードするポリヌクレオチド
WO2001085921A2 (fr) * 2000-05-12 2001-11-15 Merck Patent Gmbh Nouvelle serine-threonine kinase-4
EP1158001B1 (fr) * 2000-05-26 2007-11-14 F. Hoffmann-La Roche Ag Un acide nucléique produit excessivement dans des cellules tumorales humaines, une protéine codée par ledit acide nucléique et un procédé de diagnose de tumeurs
AU7634301A (en) * 2000-05-26 2001-12-03 Bayer Aktiengesellschaft Regulation of human p78-like serine/threonine kinase
DE10027170A1 (de) * 2000-05-31 2001-12-13 Schering Ag Humanes PEM als Target für die Fertilitätskontrolle
US7098311B2 (en) * 2000-06-02 2006-08-29 Brigham And Women's Hospital Fusion of jAZF1 and jjAZ1 genes in endometrial stromal tumors
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU6531101A (en) * 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU6604901A (en) * 2000-06-05 2001-12-17 Bayer Aktiengesellschaft Regulation of human hm74-like g protein coupled receptor
US6323016B1 (en) 2000-06-09 2001-11-27 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
EP1287029A2 (fr) * 2000-06-09 2003-03-05 Corixa Corporation Compositions et procedes pour la therapie et le diagnostic du cancer du colon
EP2075253A1 (fr) * 2000-06-23 2009-07-01 Genentech, Inc. Méthodes et composés pour la diagnose et le traitement de troubles associés à l'angiogenèse
AU2001270215A1 (en) * 2000-06-27 2002-01-08 Curagen Corporation Novel polynucleotides and polypeptides encoded thereby
US7094587B2 (en) 2000-06-27 2006-08-22 Millennium Pharmaceuticals, Inc. 16002 Molecules and uses therefor
US6774223B2 (en) 2000-06-28 2004-08-10 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
WO2002002761A2 (fr) * 2000-06-30 2002-01-10 Millennium Pharmaceuticals, Inc. 57658, nouvelle uridine kinase humaine et utilisations correspondantes
AU2001271843A1 (en) * 2000-07-07 2002-01-21 Incyte Genomics, Inc. Gtp-binding proteins
AU2001273239A1 (en) * 2000-07-07 2002-01-21 Incyte Genomics, Inc. Transporters and ion channels
US6740751B2 (en) 2000-07-18 2004-05-25 Board Of Regents, The University Of Texas System Methods and compositions for stabilizing microtubules and intermediate filaments in striated muscle cells
AU8762901A (en) * 2000-07-25 2002-02-05 Merck Patent Gmbh Novel protein containing ring finger domaine r1p4
AU2001277202A1 (en) * 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-ras/rerg protein and related reagents and methods of use thereof
AU2001277200A1 (en) * 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-cad protein and related reagents and methods of use thereof
EP1657254A3 (fr) * 2000-08-01 2006-06-07 Genentech, Inc. Polypeptide, acides nucléiques le codant, et leur utilisation pour le diagnostic du cancer
US7335732B2 (en) 2000-08-01 2008-02-26 Genentech, Inc. PRO9799 polypeptides
EP1315431A1 (fr) * 2000-08-02 2003-06-04 Millennium Pharmaceuticals, Inc. Membre de la famille du facteur de liberation du gtp humain (15368) et ses utilisations
WO2002010217A2 (fr) 2000-08-02 2002-02-07 The Johns Hopkins University Profils d'expression de cellules endotheliales
WO2002012330A2 (fr) * 2000-08-04 2002-02-14 Zymogenetics, Inc. Zzp1, proteine humaine secretee
US6943245B2 (en) 2000-08-10 2005-09-13 Board Of Regents, The University Of Texas System Tumor suppressor CAR-1
JP2004506422A (ja) * 2000-08-11 2004-03-04 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 新規マイトジェン活性化キナーゼ
EP1326985A1 (fr) * 2000-08-18 2003-07-16 MERCK PATENT GmbH Identification d'un gene d'acetyltransferase n-terminale humaine
US6706513B2 (en) 2000-08-21 2004-03-16 Bristol-Myers Squibb Company Adenosine deaminase homolog
JP2004519217A (ja) * 2000-08-21 2004-07-02 インサイト・ゲノミックス・インコーポレイテッド 微小管関連タンパク質およびチューブリン
WO2002016579A2 (fr) * 2000-08-24 2002-02-28 Eli Lilly And Company Acides nucleiques, vecteurs, cellules hotes, polypeptides et utilisations de ces derniers
CA2705366A1 (fr) * 2000-08-28 2002-03-07 Agensys, Inc. Acide nucleique et proteine correspondante denommes 85p1b3 utilises dans le traitement et la detection de cancers
CA2420902A1 (fr) * 2000-08-28 2002-03-07 Craig A. Rosen 18 proteines humaines secretees
AU2001284176A1 (en) * 2000-08-28 2002-03-13 Astrazeneca Ab Molecules involved in the regulation of insulin in resistance syndrome (irs)
AU2002210464A1 (en) * 2000-08-30 2002-03-13 Bayer Aktiengesellschaft Regulation of human aminotransferase-like enzyme
WO2002018577A2 (fr) * 2000-08-30 2002-03-07 Millennium Pharmaceuticals, Inc. Nouveau facteur de terminaison du gtp humain 48921 et ses utilisations
AU2001286714A1 (en) * 2000-08-30 2002-03-13 Millennium Pharmaceuticals, Inc. 54370, a novel human sulfate transporter and uses therefor
US7153669B2 (en) 2000-09-05 2006-12-26 Amgen Inc. Nucleic acids encoding MK61 receptors
US20020142464A1 (en) * 2000-09-08 2002-10-03 Millennium Pharmaceuticals, Inc. 38646, a novel guanine nucleotide exchange factor and uses therefor
US6372468B1 (en) * 2000-09-14 2002-04-16 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
US20040048245A1 (en) * 2000-10-05 2004-03-11 Shimkets Richard A. Novel human proteins, polynucleotides encoding them and methods of using the same
WO2002031126A2 (fr) * 2000-10-11 2002-04-18 Bayer Aktiengesellschaft Regulation d'une peptidyl-prolyl cis-trans isomerase de type cyclophiline humaine
US20020064831A1 (en) * 2000-10-12 2002-05-30 The Texas A&M University System Nucleic acid sequences encoding CMG proteins, CMG proteins, and methods for their use
EP1474528A4 (fr) * 2000-10-13 2006-06-14 Protein Design Labs Inc Procedes de diagnostic du cancer de la prostate, compositions et procedes de criblage de modulateurs du cancer de la prostate
WO2002062945A2 (fr) 2000-10-25 2002-08-15 Diadexus, Inc. Compositions et techniques relatives a des genes et a des proteines specifiques du poumon
WO2002038743A2 (fr) * 2000-11-09 2002-05-16 Glaxo Group Limited Enzyme
EP1349934A2 (fr) 2000-11-20 2003-10-08 Diadexus, Inc. Compositions et methodes relatives a des genes et des proteines specifiques aux seins
AU2001297765A1 (en) * 2000-12-05 2002-10-21 Incyte Genomics, Inc. Ligases
US7776523B2 (en) 2000-12-07 2010-08-17 Novartis Vaccines And Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
EP1339845A2 (fr) 2000-12-07 2003-09-03 ZymoGenetics, Inc. Proteine associee au complement adipocyte zacrp3x2
WO2002048328A2 (fr) * 2000-12-14 2002-06-20 Pe Corporation (Ny) Proteines kinases humaines isolees, molecules d'acide nucleique codant des proteines kinases humaines et utilisations associees
US20020142376A1 (en) * 2000-12-20 2002-10-03 Gennady Merkulov Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
IL155687A0 (en) 2000-12-22 2003-11-23 Bristol Myers Squibb Co Polynucleotides encoding hlrrsi1 polypeptides
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US6423521B1 (en) 2000-12-28 2002-07-23 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002053591A1 (fr) * 2000-12-30 2002-07-11 Lion Bioscience Ag Cofacteur de recepteur nucleaire mammalien cf12 et ses procedes d'utilisation
US20030219739A1 (en) * 2001-01-30 2003-11-27 Glass David J. Novel nucleic acid and polypeptide molecules
WO2002098917A2 (fr) * 2001-02-12 2002-12-12 Curagen Corporation Proteines, polynucleotides codant pour lesdites proteines et methodes d'utilisation desdites proteines
EP1637601A3 (fr) * 2001-02-21 2006-03-29 Curagen Corporation Protéines , polynucléotides codant pour ces protéines et procédés d'utilisation
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
AU2002250143A1 (en) * 2001-03-16 2002-10-03 Eli Lilly And Company Lp mammalian proteins; related reagents
US6913904B2 (en) * 2001-03-27 2005-07-05 Applera Corporation Isolated human Ras-like proteins, nucleic acid molecules encoding these human Ras-like proteins, and uses thereof
AU2002258626B2 (en) 2001-04-10 2007-01-18 Agensys, Inc. Nucleid acid and corresponding protein entitled 158P3D2 useful in treatment and detection of cancer
EP2280030A3 (fr) 2001-04-10 2011-06-15 Agensys, Inc. Acides nucléiques et protéines correspondantes utiles dans la détection et le traitement des différents cancers
EP1573022B1 (fr) 2001-04-10 2011-06-08 Agensys, Inc. Acide nucleique et proteine correspondante intitulee 184p1e2, utilises dans le traitement et la detection de cancers
WO2002086113A2 (fr) * 2001-04-24 2002-10-31 Isis Innovation Ltd Enzyme et marqueur snp pour le depistage d'une maladie
JPWO2002088175A1 (ja) * 2001-04-24 2004-08-19 大塚製薬株式会社 クローン病抗体結合性ペプチド及びクローン病の検査方法
KR100882762B1 (ko) 2001-05-07 2009-02-09 시오노기세이야쿠가부시키가이샤 혈관신생 마커로서 사용되는 폴리펩티드 및 이의 ｄｎａ
AU2002314048A1 (en) * 2001-05-09 2002-11-18 Bayer Aktiengesellschaft Regulation of human phosphatidic acid phosphatase type 2c-like protein
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
WO2003000901A2 (fr) * 2001-06-26 2003-01-03 Decode Genetics Ehf. Acides nucleiques codant des proteines kinases
US20030120040A1 (en) 2001-06-29 2003-06-26 Genentech, Inc. Secreted and Transmembrane polypeptides and nucleic acids encoding the same
GB2399086A (en) * 2001-08-02 2004-09-08 Aeomica Inc Human zinc finger containing gene MDZ4
WO2003031568A2 (fr) * 2001-08-17 2003-04-17 Incyte Genomics, Inc. Molecules de signalisation intracellulaire
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
WO2003023063A1 (fr) * 2001-09-07 2003-03-20 Sankyo Company, Limited Methode d'estimation du risque d'apparition de diabetes
WO2003025175A2 (fr) * 2001-09-17 2003-03-27 Molecular Engines Laboratories Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
WO2003040369A2 (fr) * 2001-09-17 2003-05-15 Molecular Engines Laboratories Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
CA2417455C (fr) 2001-09-28 2008-01-29 Brigham Young University Variants nouveaux de la cyclooxygenase et methodes d'utilisation
WO2003038087A1 (fr) 2001-10-04 2003-05-08 Kansai Technology Licensing Organization Co., Ltd. Promoteur du gene dr5 et promoteur du gene siah-1
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
WO2003031607A1 (fr) * 2001-10-10 2003-04-17 Bayer Healthcare Ag Regulation de deshydrogenase/reductase des chaines courtes humaine
DE60220621T2 (de) 2001-11-09 2008-03-06 Proteologics, Inc. Posh Nukleinsäure, Polypeptide und darauf bezogene Verfahren
AU2002365162A1 (en) 2001-11-14 2003-07-09 Northwestern University Self-assembly and mineralization of peptide-amphiphile nanofibers
CA2468145A1 (fr) * 2001-11-21 2003-05-30 Japan Science And Technology Agency Facteurs de transcription de gene de la choree de huntington
US7151162B2 (en) 2001-12-06 2006-12-19 The University Of Children's Hospital Of Both Cantons Of Basel Nuclear protein
AU2002339697A1 (en) * 2001-12-19 2003-06-30 Genset S.A. Gmg-5 polynucleotides and polypeptides and uses thereof
JP2003245084A (ja) * 2001-12-20 2003-09-02 Morinaga Milk Ind Co Ltd 脳梁又は精子の形成不全の診断及び治療に有用な新規遺伝子、並びにその用途
DE10163467A1 (de) * 2001-12-21 2003-11-27 Axaron Bioscience Ag Protein 24B2 und zugrundliegende DNA-Sequenz
US6759222B2 (en) 2002-01-02 2004-07-06 Millennium Pharmaceuticals, Inc. 14815, a human kinase family member and uses therefor
AU2003235631A1 (en) * 2002-01-15 2003-07-30 Bayer Aktiengesellschaft Human subtilisin/kexin-like convertase
AU2003205611A1 (en) * 2002-01-15 2003-07-30 Medigene Ag Dilated cardiomyopathy associated gene-2 (dcmag-2): a cytoplasmatic inducer of sarcomeric remodeling in cardiomyocytes
US7371719B2 (en) 2002-02-15 2008-05-13 Northwestern University Self-assembly of peptide-amphiphile nanofibers under physiological conditions
EP1338609A1 (fr) * 2002-02-21 2003-08-27 MEMOREC Stoffel GmbH-Medizinisch-Molekulare Entwicklung, Köln Un outre récepteur KDR et son utilisation
CA2478271A1 (fr) * 2002-03-05 2003-09-18 Applera Corporation Proteines transporteuses humaines isolees, molecules d'acide nucleique codant celles-ci, et utilisations associees
GB2388113A (en) * 2002-03-06 2003-11-05 Oxford Glycosciences B-cell malignancy-associated protein
DK1918386T3 (da) 2002-03-13 2012-01-02 Genomic Health Inc Genekspressionsprofiler i biopsier af tumorvæv
AU2003220913A1 (en) * 2002-03-19 2003-09-29 Tanabe Seiyaku Co., Ltd. Novel g protein-coupled recepotrs and genes thereof
US7527935B2 (en) 2002-03-19 2009-05-05 Mitsubishi Tanabe Pharma Corporation G-protein coupled receptor having eicosanoid as ligand and gene thereof
GB0206684D0 (en) * 2002-03-21 2002-05-01 Babraham Inst Novel proteins
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
US7329502B2 (en) 2002-04-25 2008-02-12 The United States Of America As Represented By The Department Of Health And Human Services ZAP-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
JP2004041003A (ja) * 2002-05-17 2004-02-12 Takeda Chem Ind Ltd 新規タンパク質、そのｄｎａおよびその用途
EP2275118A3 (fr) 2002-05-29 2011-10-19 DeveloGen Aktiengesellschaft Proteines specifiques du pancreas
AU2003237367A1 (en) 2002-06-03 2003-12-19 Chiron Corporation Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
DK1513934T3 (da) 2002-06-06 2011-05-02 Oncotherapy Science Inc Gener og polypeptider relateret til humane coloncancersygdomme
JP2005535308A (ja) 2002-06-13 2005-11-24 カイロン コーポレイション Ｈｍｌ−２ポリペプチド発現用ベクター
JP4186004B2 (ja) 2002-08-14 2008-11-26 独立行政法人産業技術総合研究所 新規ｎ−アセチルガラクトサミン転移酵素およびそれをコードする核酸
AU2003243151A1 (en) * 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
WO2004018518A1 (fr) * 2002-08-23 2004-03-04 Japan Science And Technology Agency Peptides antigeniques de tumeur cancereuse solide humains, polynucleotides codant pour ceux-ci et utilisation de ceux-ci
AU2003250989A1 (en) * 2002-08-27 2004-03-19 Epigenomics Ag Method and nucleic acids for the analysis of breast cell proliferative disorders
US7452969B2 (en) 2002-08-30 2008-11-18 Licentia Ltd Neurotrophic factor protein and uses thereof
CN1703524B (zh) * 2002-09-30 2010-04-07 肿瘤疗法科学股份有限公司 与人胰腺癌相关的基因和多肽
EP1552310A2 (fr) * 2002-10-17 2005-07-13 EVOTEC Neurosciences GmbH L'utilisation de la proteine et du gene de la nicotinamide mononucleotide adenylyltransferase 2 (nmnat-2) pour le diagnostique et la therapie des maladies neurodegeneratives
AU2002952216A0 (en) * 2002-10-23 2002-11-07 The Walter And Eliza Hall Institute Of Medical Research Novel therapeutic molecules
US7554021B2 (en) 2002-11-12 2009-06-30 Northwestern University Composition and method for self-assembly and mineralization of peptide amphiphiles
EP1570080A4 (fr) 2002-11-15 2006-03-01 Genomic Health Inc Etablissement de profils d'expressions genetique du cancer a recepteur de facteur de croissance epidermique positif
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2002953341A0 (en) * 2002-12-13 2003-01-09 The Walter And Eliza Hall Institute Of Medical Research A novel phosphoprotein
AU2003287764B2 (en) * 2002-12-13 2010-01-21 The Walter And Eliza Hall Institute Of Medical Research A novel phosphoprotein
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004070025A2 (fr) * 2003-02-05 2004-08-19 Juan Saus Nouvelles isoformes de la proteine liant l'antigene de goodpasture et troubles induits par une proteine incorrectement repliee
EP1445614A1 (fr) * 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Méthodes d'évaluation in vitro de l'état de progression d'un virus HIV chez un individu
US7074891B2 (en) * 2003-02-07 2006-07-11 Posco Leukocyte stimulating peptides
AU2004213871B9 (en) 2003-02-20 2009-09-03 Genomic Health, Inc. Use of intronic RNA to measure gene expression
WO2004078784A1 (fr) * 2003-03-04 2004-09-16 Astellas Pharma Inc. Nouveau gene associe a des conditions fibreuses
PL378582A1 (pl) 2003-03-19 2006-05-02 Biogen Idec Ma Inc. Białko wiążące receptor Nogo
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
EP3470535B1 (fr) 2003-06-24 2020-04-01 Genomic Health, Inc. Prédiction de probabilité de récurrence de cancer
US7526387B2 (en) 2003-07-10 2009-04-28 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
ATE528397T1 (de) 2003-08-08 2011-10-15 Perseus Proteomics Inc Bei krebs überexprimiertes gen
US20050136434A1 (en) * 2003-08-12 2005-06-23 Mai Xu Isolated heat-inducible cell surface protein and hyperthermia-based tumor immunotargeting therapy
TW200517503A (en) * 2003-09-10 2005-06-01 Japan Science & Tech Agency Group of genes differentially expressed in peripheral blood cells and diagnostic method and assay method using the same
EP1667712B1 (fr) * 2003-10-02 2010-07-21 GlaxoSmithKline Biologicals S.A. Antigenes de b. pertussis et leur utilisation dans la vaccination
CA2541006C (fr) 2003-10-03 2015-02-17 Brigham And Women's Hospital Ligands de tim-3 et methodes associees
WO2005040791A2 (fr) * 2003-10-21 2005-05-06 Bayer Healthcare Ag Diagnostics et therapeutiques pour maladies liees au recepteur de peptides similaire a la somatostatine et a l'angiogenine (salpr)
US20050255560A1 (en) * 2003-11-21 2005-11-17 Zeren Gao Ztnf11, a tumor necrosis factor
CA2549164A1 (fr) 2003-12-05 2005-06-23 Northwestern University Amphiphiles peptidiques a assemblage automatique et procedes associes d'administration de facteur de croissance
JP4718490B2 (ja) 2003-12-23 2011-07-06 ジェノミック ヘルス， インコーポレイテッド フラグメント化ｒｎａの全般的増幅
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
PT3556866T (pt) 2004-03-02 2021-04-30 Univ Johns Hopkins Mutações do gene de pik3ca em cancros humanos
TW200539890A (en) 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
WO2005090569A1 (fr) * 2004-03-24 2005-09-29 The Council Of The Queensland Institute Of Medical Research Cancer et acides nucleiques et proteines de testicule vsm1 et vsm2, et leurs utilisations
DK2163650T3 (en) 2004-04-09 2015-11-02 Genomic Health Inc Genekspressionsmarkører for prediction of response to chemotherapy
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2005118832A2 (fr) * 2004-06-01 2005-12-15 Bayer Healthcare Ag Agents diagnostiques et therapeutiques pour des maladies associees a une proteine de type kinase regulee par serum/glucocorticoide (sgkl)
AU2005258335B2 (en) 2004-06-24 2011-03-17 Biogen Ma Inc. Treatment of conditions involving demyelination
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
US7985831B2 (en) * 2004-08-05 2011-07-26 Toagosei Co., Ltd. Crohn's disease antibody epitope peptide and reagent for testing Crohn's disease
HUE051605T2 (hu) 2004-11-05 2021-03-01 Nsabp Found Inc Kemoterápiára adott válasz elõrejelzése génexpressziós markereket alkalmazva
CA2585561C (fr) 2004-11-05 2018-07-17 Genomic Health, Inc. Resultat de groupe esr1, pgr, bcl2 et scube2 comme indicateurs de pronostic de cancer du sein et de prediction de la reponse au traitement
EP2845865A1 (fr) 2004-11-12 2015-03-11 Xencor Inc. Variantes Fc avec liaison altérée en FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
CA2598251A1 (fr) 2005-03-04 2006-09-14 Northwestern University Epitopes angiogeniques de liaison a l'heparine, amphiphiles peptidiques, compositions auto-assemblees et procedes d'utilisation associes
WO2006120019A2 (fr) * 2005-05-13 2006-11-16 Centre National De La Recherche Scientifique Utilisation de nouveau codage genique pour nouvel element de la famille mcm2-8 dans les compositions pharmaceutiques
MX2008000253A (es) 2005-07-08 2008-04-02 Biogen Idec Inc Anticuerpos de sp35 y usos de los mismos.
WO2007014338A2 (fr) * 2005-07-26 2007-02-01 Siemens Medical Solutions Diagnostics Polymorphismes de nucleotides uniques a susceptibilite par rapport a une maladie cardio-vasculaire
WO2007037601A1 (fr) * 2005-09-28 2007-04-05 Knu-Industry Cooperation Foundation Polypeptide inhibant la transmigration de leucocytes ou la croissance et/ou la métastase de cellules cancéreuses, et une protéine de fusion de celui-ci
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
DE602005023550D1 (de) 2005-12-14 2010-10-21 Licentia Ltd Verwendungen eines neurotrophischen Faktors
EP2044216A2 (fr) * 2006-07-03 2009-04-08 Exonhit Therapeutics SA Produits de la transcription spécifiques de la prostate et leur utilisation pour des thérapeutiques et des diagnostics du cancer de la prostate
EP2066810A2 (fr) * 2006-09-08 2009-06-10 Corixa Corporation Procédés, compositions, et kits de détection et de surveillance d'un cancer du colon
US8076295B2 (en) 2007-04-17 2011-12-13 Nanotope, Inc. Peptide amphiphiles having improved solubility and methods of using same
US8999634B2 (en) * 2007-04-27 2015-04-07 Quest Diagnostics Investments Incorporated Nucleic acid detection combining amplification with fragmentation
GB0805159D0 (en) 2008-03-19 2008-04-23 Sancho Madrid David Immune modulation via C-type lectin
ES2553270T3 (es) * 2007-07-27 2015-12-07 Immatics Biotechnologies Gmbh Nuevo epítopo inmunogénico para inmunoterapia
US7863021B2 (en) 2007-09-05 2011-01-04 Celera Corporation Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
WO2009034661A1 (fr) * 2007-09-12 2009-03-19 Toppan Printing Co., Ltd. Procédé de diagnostic et induction d'une résistance à un virus
ES2401233T3 (es) 2007-10-17 2013-04-18 Universidad de Córdoba Isoformas del receptor tipo 5 de somatostatina humana producidas por tratamiento alternativo y pares de oligonucleótidos para la detección de las mismas por PCR
HUE024903T2 (en) 2007-12-26 2016-02-29 Xencor Inc FC variants with modified binding to FCRN
GB0803352D0 (en) * 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
ES2584438T3 (es) 2008-03-21 2016-09-27 Universiteit Hasselt Biomarcadores para artritis reumatoide
EP2315779A2 (fr) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprenant des anticorps anti-lingo ou leurs fragments
ES2536465T3 (es) 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
CA2758687A1 (fr) 2008-11-14 2010-05-20 Gen-Probe Incorporated Compositions, kits et procedes pour la detection d'acide nucleique de campylobacter
WO2010062960A2 (fr) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center Méthodes de détermination d'une réceptivité à une thérapie par anti-tnfα lors d’une maladie intestinale inflammatoire
WO2010066018A1 (fr) * 2008-12-09 2010-06-17 Alethia Biotherapeutics Inc. Nouveau variant rétroviral endogène humain d’erv3 et utilisations de celui-ci pour diagnostiquer le cancer des ovaires
WO2010120830A1 (fr) 2009-04-13 2010-10-21 Northwestern University Nouvelles structures peptidiques pour la régénération des cartilages et procédés pour les utiliser
WO2011028952A1 (fr) 2009-09-02 2011-03-10 Xencor, Inc. Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes
ES2802623T3 (es) 2010-01-27 2021-01-20 Massachusetts Inst Technology Agentes polipeptídicos técnicamente diseñados para la neutralización dirigida de amplio espectro de la gripe
AU2011312417B2 (en) 2010-09-29 2015-08-20 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
DK2651430T3 (en) * 2010-12-14 2018-08-27 Hananja Ehf Biological activity of placental protein 13
PT3489254T (pt) 2012-04-30 2022-12-30 Biocon Ltd Proteínas de fusão direcionadas/imunomoduladoras e seus métodos de fabrico
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer
CN104470541A (zh) 2012-05-14 2015-03-25 比奥根艾迪克Ma公司 用于治疗涉及运动神经元的疾患的lingo-2拮抗剂
WO2013174404A1 (fr) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
CN105073776B (zh) 2012-11-13 2019-04-12 拜恩科技股份公司 用于治疗表达紧密连接蛋白的癌症疾病的制剂
WO2014127785A1 (fr) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
US9023353B2 (en) * 2013-03-13 2015-05-05 The Board Of Trustees Of The University Of Arkansas Anti-(+)—methamphetamine monoclonal antibodies
WO2014146672A1 (fr) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer
CA2908553A1 (fr) 2013-03-27 2014-10-02 Cedars-Sinai Medical Center Attenuation ou regression de la fibrose et de l'inflammation par inhibition de la fonction tl1a et des voies de signalisation connexes
JP7019233B2 (ja) 2013-07-11 2022-02-15 モデルナティエックス インコーポレイテッド ＣＲＩＳＰＲ関連タンパク質をコードする合成ポリヌクレオチドおよび合成ｓｇＲＮＡを含む組成物ならびに使用方法
WO2015010108A1 (fr) 2013-07-19 2015-01-22 Cedars-Sinai Medical Center Signature de la voie de signalisation de tl1a (tnfsf15)
JP6915987B2 (ja) 2013-09-25 2021-08-11 シトムクス セラピューティクス，インコーポレイティド マトリックスメタロプロテイナーゼ基質及び他の切断可能部分並びにそれらの使用方法
CA2925658C (fr) 2013-10-01 2022-12-06 Mie University Antigene contenant une sequence d'interepitope favorisant la presentation d'antigene aux cellules t
IL302642A (en) 2014-01-31 2023-07-01 Cytomx Therapeutics Inc Polypeptide substrates that activate matriptase and U-plasminogen and other cleavable groups, preparations containing them and their uses
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
EP3307070A4 (fr) * 2015-06-12 2019-01-02 Emory University Compositions de croissance et de survie pour des cellules capables de produire des anticorps et procédés associés
KR20180127416A (ko) 2016-03-17 2018-11-28 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
US20200330606A1 (en) * 2016-03-29 2020-10-22 Valkyrie Therapeutics Inc. Modulation of structural maintenance of chromosome-1 expression
US9611297B1 (en) 2016-08-26 2017-04-04 Thrasos Therapeutics Inc. Compositions and methods for the treatment of cast nephropathy and related conditions
US11125757B2 (en) 2017-05-26 2021-09-21 Emory University Methods of culturing and characterizing antibody secreting cells
EP3508499A1 (fr) 2018-01-08 2019-07-10 iOmx Therapeutics AG Anticorps ciblant et d'autres modulateurs d'un gène d'immunoglobuline associé à une résistance contre des réponses immunitaires antitumorales et leurs utilisations
AU2020261435A1 (en) * 2019-04-26 2021-11-25 Sangamo Therapeutics, Inc. Engineering AAV
JP2022538688A (ja) 2019-07-05 2022-09-05 イオックス セラピューティクス アーゲー ＩＧＳＦ１１（ＶＳＩＧ３）のＩｇＣ２に結合する抗体及びその使用
WO2021083958A1 (fr) * 2019-10-29 2021-05-06 Specialites Pet Food Nouveaux peptides induisant la satiété
EP4149952A1 (fr) * 2020-05-12 2023-03-22 Institut Curie Épitopes néo-antigéniques associés à des mutations sf3b1
WO2022008027A1 (fr) 2020-07-06 2022-01-13 Iomx Therapeutics Ag Anticorps de liaison à l'igv d'igsf11 (vsig3) et leurs utilisations
CN117529492A (zh) * 2021-01-21 2024-02-06 鹿特丹伊拉斯谟大学医疗中心 用于治疗的t细胞
US20220260597A1 (en) * 2021-02-18 2022-08-18 Beren Therapeutics P.B.C. Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins
WO2023225602A1 (fr) * 2022-05-20 2023-11-23 Medikine, Inc. Polypeptides de liaison au récepteur de l'interleukine-18 et leurs utilisations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925521A (en) * 1997-03-31 1999-07-20 Incyte Pharmaceuticals, Inc. Human serine carboxypeptidase
US5948641A (en) * 1997-05-29 1999-09-07 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a metal response element binding protein
US5972660A (en) * 1997-10-22 1999-10-26 Incyte Pharmaceuticals, Inc. Human hydroxypyruvate reductase

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4446240A (en) * 1981-01-30 1984-05-01 Nerenberg Samuel T Pancreas specific protein systems
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US6080540A (en) * 1990-04-20 2000-06-27 Cold Spring Harbor Laboratory Cloning of mammalian genes in microbial organisms and methods for pharmacological screening
JP2845623B2 (ja) * 1990-11-26 1999-01-13 アメリカ合衆国 細胞のストレス転写因子
US5721352A (en) * 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
US5840870A (en) * 1995-12-29 1998-11-24 Incyte Pharmaceuticals, Inc. Polynucleotides PANC1A and PANC1B associated with pancreatic cancer
WO1999014234A2 (fr) * 1997-09-17 1999-03-25 Genentech, Inc. Stimulation ou inhibition de l'angiogenese et de la cardiovascularisation
US5912160A (en) * 1995-08-22 1999-06-15 Thomas Jefferson University Gab1, Grb2 binding protein, and compositions for making and methods of using the same
JP3462313B2 (ja) * 1995-08-24 2003-11-05 キッコーマン株式会社 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体ｄｎａ及び変異型ウリカーゼの製造法
US5998165A (en) * 1995-12-29 1999-12-07 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a protein associated with pancreatic cancer
JP2000511410A (ja) * 1996-04-29 2000-09-05 ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン ナンセンス介在ｒｎａ崩壊の哺乳動物の調節因子
US6500934B1 (en) * 1996-07-24 2002-12-31 Michael Rush Lerner Bivalent agonists for G-protein coupled receptors
US5976834A (en) * 1997-01-09 1999-11-02 Smithkline Beecham Corporation cDNA clone HNFJD15 that encodes a novel human 7-transmembrane receptor
CA2232743A1 (fr) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation Tl5, homologue tnf
WO1998045435A2 (fr) * 1997-04-10 1998-10-15 Genetics Institute, Inc. MARQUEURS SECRETES DE SEQUENCE EXPRIMEE (sEST)
IT1291110B1 (it) * 1997-04-15 1998-12-29 Istituto Europ Di Oncologia S Interattori intracellulari e specificita' di legame del dominio eh
WO1998055620A1 (fr) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Element ntn-2 de la famille des ligands du tnf
US5932442A (en) * 1997-09-23 1999-08-03 Incyte Pharmaceuticals, Inc. Human regulatory molecules
DE19818598A1 (de) * 1998-04-19 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Pankreasnormalgewebe
CA2327317A1 (fr) * 1998-04-29 1999-11-04 Genesis Research And Development Corporation Limited Polynucleotides isoles de cellules de la peau et leurs procedes d'utilisation
US6262249B1 (en) * 1998-06-23 2001-07-17 Chiron Corporation Pancreatic cancer genes
CA2296792A1 (fr) * 1999-02-26 2000-08-26 Genset S.A. Sequences marqueurs exprimees et proteines humaines codees

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925521A (en) * 1997-03-31 1999-07-20 Incyte Pharmaceuticals, Inc. Human serine carboxypeptidase
US5948641A (en) * 1997-05-29 1999-09-07 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a metal response element binding protein
US5972660A (en) * 1997-10-22 1999-10-26 Incyte Pharmaceuticals, Inc. Human hydroxypyruvate reductase

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1623993A2 (fr) * 1999-09-01 2006-02-08 Genetech, Inc. Protéines sécrétées et transmembranaires et acides nucléiques les codant
WO2001081586A2 (fr) * 2000-04-26 2001-11-01 Millennium Pharmaceuticals, Inc. 21657, deshydrogenase humaine a chaine courte et ses utilisations
WO2001081586A3 (fr) * 2000-04-26 2002-07-18 Millennium Pharm Inc 21657, deshydrogenase humaine a chaine courte et ses utilisations
WO2001083754A2 (fr) * 2000-05-02 2001-11-08 Immusol, Incorporated Regulateurs cellulaires d'agents infectieux et methodes d'utilisations
WO2001083754A3 (fr) * 2000-05-02 2002-10-03 Immusol Inc Regulateurs cellulaires d'agents infectieux et methodes d'utilisations
US6808876B1 (en) 2000-05-02 2004-10-26 Immusol, Inc. Cellular regulators of infectious agents and methods of use
WO2001096542A2 (fr) * 2000-06-15 2001-12-20 Millennium Pharmaceuticals, Inc. 23680, nouvelle aminotransferase humaine et utilisations de celle-ci
WO2001096542A3 (fr) * 2000-06-15 2002-06-06 Millennium Pharm Inc 23680, nouvelle aminotransferase humaine et utilisations de celle-ci
WO2001096546A3 (fr) * 2000-06-16 2002-08-08 Incyte Genomics Inc Proteine-phosphatases
WO2001096546A2 (fr) * 2000-06-16 2001-12-20 Incyte Genomics, Inc. Proteine-phosphatases
WO2002000861A2 (fr) * 2000-06-26 2002-01-03 Millennium Pharmaceuticals, Inc. 46619, une nouvelle synthase beta-cetoacyle et utilisations de cette derniere
WO2002000861A3 (fr) * 2000-06-26 2002-07-04 Millennium Pharm Inc 46619, une nouvelle synthase beta-cetoacyle et utilisations de cette derniere
WO2002006453A3 (fr) * 2000-07-18 2002-12-05 Bayer Ag Regulation de protease a serine humaine de type desc1
WO2002018552A3 (fr) * 2000-08-30 2003-03-13 Bayer Ag Regulation d'enzyme humaine de type aminotransferase
WO2002018552A2 (fr) * 2000-08-30 2002-03-07 Bayer Aktiengesellschaft Regulation d'enzyme humaine de type aminotransferase
WO2002018582A3 (fr) * 2000-08-31 2002-08-08 Millennium Pharm Inc 62112, nouvelle deshydrogenase humaine et ses utilisations
US7166428B2 (en) 2000-08-31 2007-01-23 Millennium Pharmaceuticals, Inc. 62112, a novel human dehydrogenase and uses thereof
WO2002018582A2 (fr) * 2000-08-31 2002-03-07 Millennium Pharmaceuticals, Inc. 62112, nouvelle deshydrogenase humaine et ses utilisations
WO2002020754A2 (fr) * 2000-09-05 2002-03-14 Incyte Genomics, Inc. Molecules utilisees a des fins diagnostiques et therapeutiques
WO2002020754A3 (fr) * 2000-09-05 2003-09-25 Incyte Genomics Inc Molecules utilisees a des fins diagnostiques et therapeutiques
WO2002022806A3 (fr) * 2000-09-14 2003-01-16 Pe Corp Ny Proteines de phospholipase humaines isolees, molecules d'acides nucleiques codant les proteines de phospholipase humaines et utilisations associees
WO2002031132A3 (fr) * 2000-10-11 2003-03-13 Millennium Pharm Inc Nouvel element de la famille des phosphatases humaines a double specificite, appele 8843, et utilisation de ce dernier
WO2002034922A3 (fr) * 2000-10-20 2003-08-28 Pe Corp Ny Proteines humaines isolees metabolisant les medicaments, molecules d'acide nucleique codant les proteines humaines metabolisant les medicaments et utilisations correspondantes
WO2002036781A2 (fr) * 2000-10-31 2002-05-10 Bayer Aktiengesellschaft Regulation de la glutathione-s-transferase humaine
WO2002036781A3 (fr) * 2000-10-31 2003-02-06 Bayer Ag Regulation de la glutathione-s-transferase humaine
WO2003057870A1 (fr) * 2002-01-07 2003-07-17 Bayer Healthcare Ag Proteine humaine analogue a la phosphatase de l'acide phosphatidique de type 2
WO2003062429A1 (fr) * 2002-01-23 2003-07-31 Yamanouchi Pharmaceutical Co., Ltd. Nouvelle serine protease
WO2004009626A1 (fr) * 2002-07-22 2004-01-29 Yamanouchi Pharmaceutical Co., Ltd. Nouveau gene associe a l'arthrite rhumatoide
WO2005024055A1 (fr) * 2003-09-05 2005-03-17 Garvan Institute Of Medical Research Procedes de diagnostic et de pronostic du cancer ovarien ii
US9845344B2 (en) 2004-03-30 2017-12-19 Hoba Therapeutics Aps Therapeutic use of a growth factor, NsG33
US8334264B2 (en) 2008-07-24 2012-12-18 NsGenee A/S Therapeutic use of a growth factor, METRNL
US10034918B2 (en) 2008-07-24 2018-07-31 Hoba Therapeutics Aps Therapeutic use of a growth factor, METRNL
US9675669B2 (en) 2008-07-24 2017-06-13 Hoba Therapeutics Aps Therapeutic use of a growth factor, METRNL
US9068015B2 (en) 2008-07-24 2015-06-30 Nsgene A/S Therapeutic use of a growth factor, METRNL
US9314502B2 (en) 2010-10-01 2016-04-19 Nsgene A/S Treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
US8815810B2 (en) 2010-10-01 2014-08-26 Nsgene A/S Treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
US8404642B2 (en) 2010-10-01 2013-03-26 Nsgene A/S Treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
US9474786B2 (en) 2011-09-05 2016-10-25 Nsgene A/S Treatment of allodynia
US9861682B2 (en) 2011-09-05 2018-01-09 Hoba Therapeutics Aps Treatment of hyperalgesia, spontaneous pain, and phantom pain
WO2013068445A1 (fr) * 2011-11-09 2013-05-16 Sanofi Diacylglycérol lipase et applications associées
EP3344776A4 (fr) * 2015-09-04 2019-09-04 Synthetic Genomics, Inc. Microorganismes modifiés pour améliorer la productivité
US10683514B2 (en) 2015-09-04 2020-06-16 Synthetic Genomics, Inc. Microorganisms engineered for increased productivity

Also Published As

Publication number Publication date
CA2392428A1 (fr) 2001-08-02
WO2001055308A2 (fr) 2001-08-02
WO2001055303A3 (fr) 2001-12-20
AU2001241414A1 (en) 2001-08-07
AU2001241410A1 (en) 2001-08-07
WO2001055207A8 (fr) 2001-09-07
WO2001055321A8 (fr) 2001-09-07
WO2001054473A2 (fr) 2001-08-02
WO2001055303A8 (fr) 2001-09-07
WO2001055323A2 (fr) 2001-08-02
CA2395849A1 (fr) 2001-08-02
WO2001055447A1 (fr) 2001-08-02
WO2001055322A8 (fr) 2001-09-07
CA2392450A1 (fr) 2001-08-16
WO2001055314A2 (fr) 2001-08-02
CA2393652A1 (fr) 2001-08-02
WO2001055163A8 (fr) 2001-09-07
WO2001055308A3 (fr) 2002-07-04
AU2001250770A1 (en) 2001-08-07
WO2001055343A8 (fr) 2001-09-07
WO2001055368A1 (fr) 2001-08-02
WO2001055315A8 (fr) 2001-09-07
CA2395693A1 (fr) 2001-08-02
CA2395816A1 (fr) 2001-08-02
WO2001055304A3 (fr) 2002-07-18
WO2001055310A8 (fr) 2001-09-07
AU2001241416A1 (en) 2001-08-07
WO2001054733A8 (fr) 2001-09-07
WO2001055387A8 (fr) 2001-12-06
WO2001055205A1 (fr) 2001-08-02
WO2001055309A3 (fr) 2002-07-18
CA2395403A1 (fr) 2001-08-02
CA2395738A1 (fr) 2002-08-02
AU4313701A (en) 2001-08-14
AU2001241415A1 (en) 2001-08-07
WO2001055202A8 (fr) 2001-09-07
WO2001055208A8 (fr) 2001-09-07
WO2001055314A3 (fr) 2002-05-02
WO2001055318A3 (fr) 2002-07-04
WO2001055367A8 (fr) 2001-12-20
WO2001055307A8 (fr) 2001-09-07
WO2001055204A8 (fr) 2001-09-07
WO2001055173A8 (fr) 2001-11-29
WO2001055207A1 (fr) 2001-08-02
CA2397407A1 (fr) 2001-08-02
WO2001055301A8 (fr) 2001-09-07
WO2001055319A2 (fr) 2001-08-02
WO2001055364A2 (fr) 2001-08-02
WO2001055316A3 (fr) 2002-04-11
WO2001055311A8 (fr) 2001-09-07
WO2001055325A2 (fr) 2001-08-02
CA2395178A1 (fr) 2001-08-02
WO2001057182A3 (fr) 2002-03-28
WO2001059064A3 (fr) 2002-03-14
CA2395666A1 (fr) 2001-08-02
WO2001055200A8 (fr) 2001-09-07
WO2001055324A8 (fr) 2001-09-07
WO2001054474A8 (fr) 2001-12-20
WO2001055320A3 (fr) 2002-04-11
WO2001055203A8 (fr) 2001-09-07
CA2392422A1 (fr) 2001-08-02
WO2001055307A3 (fr) 2002-01-10
CA2395724A1 (fr) 2001-08-02
AU2001241417A1 (en) 2001-08-07
CA2398411A1 (fr) 2001-08-02
CA2395295A1 (fr) 2001-08-02
WO2001055206A8 (fr) 2001-12-13
WO2001055316A8 (fr) 2001-09-07
CA2395885A1 (fr) 2001-08-02
WO2001055324A2 (fr) 2001-08-02
CA2392751A1 (fr) 2001-08-02
WO2001055315A2 (fr) 2001-08-02
WO2001055350A8 (fr) 2001-09-07
WO2001055202A1 (fr) 2001-08-02
WO2001055327A2 (fr) 2001-08-02
WO2001055327A3 (fr) 2002-02-28
WO2001055312A3 (fr) 2002-03-14
AU2001241406A1 (en) 2001-08-07
WO2001055200A1 (fr) 2001-08-02
WO2001055448A1 (fr) 2001-08-02
AU2001241407A1 (en) 2001-08-07
WO2001055327A8 (fr) 2001-09-07
AU4141101A (en) 2001-08-20
CA2393002A1 (fr) 2001-08-02
WO2001055350A1 (fr) 2001-08-02
WO2001055319A3 (fr) 2002-02-21
CA2394841A1 (fr) 2001-08-02
WO2001055364A3 (fr) 2002-07-04
WO2001055325A3 (fr) 2002-07-04
WO2001055316A2 (fr) 2001-08-02
WO2001055322A3 (fr) 2002-07-04
WO2001055323A8 (fr) 2001-09-07
WO2001057182A2 (fr) 2001-08-09
WO2001055310A2 (fr) 2001-08-02
CA2395787A1 (fr) 2001-08-02
WO2001055311A3 (fr) 2002-07-04
CA2395699A1 (fr) 2001-08-02
WO2001054474A2 (fr) 2001-08-02
WO2001055203A1 (fr) 2001-08-02
WO2001055304A2 (fr) 2001-08-02
CA2393618A1 (fr) 2001-08-02
WO2001055387A1 (fr) 2001-08-02
WO2001055307A2 (fr) 2001-08-02
AU2001241412A1 (en) 2001-08-07
WO2001054733A1 (fr) 2001-08-02
CA2393912A1 (fr) 2001-08-02
WO2001055447A8 (fr) 2001-09-07
AU2001241405A1 (en) 2001-08-07
WO2001055364A8 (fr) 2001-09-07
WO2001055205A8 (fr) 2001-12-13
WO2001055309A8 (fr) 2001-09-07
CA2398877A1 (fr) 2001-08-09
CA2392438A1 (fr) 2001-08-02
WO2001055367A1 (fr) 2001-08-02
WO2001055204A1 (fr) 2001-08-02
WO2001055328A3 (fr) 2002-07-04
WO2001055312A8 (fr) 2001-09-07
WO2001055308A8 (fr) 2001-09-07
WO2001055309A2 (fr) 2001-08-02
WO2001055355A8 (fr) 2001-09-07
WO2001055320A2 (fr) 2001-08-02
WO2001055321A3 (fr) 2002-07-04
AU2001241418A1 (en) 2001-08-07
WO2001055173A2 (fr) 2001-08-02
WO2001055321A2 (fr) 2001-08-02
CA2395398A1 (fr) 2001-08-02
WO2001055318A2 (fr) 2001-08-02
WO2001055343A1 (fr) 2001-08-02
WO2001055163A1 (fr) 2001-08-02
WO2001055304A8 (fr) 2001-09-07
WO2001055302A2 (fr) 2001-08-02
WO2001055312A2 (fr) 2001-08-02
WO2001055320A8 (fr) 2001-09-07
WO2001055201A1 (fr) 2001-08-02
CA2395654A1 (fr) 2001-08-02
CA2395729A1 (fr) 2001-08-02
WO2001055301A3 (fr) 2009-06-04
WO2001055319A8 (fr) 2001-09-07
WO2001055302A8 (fr) 2001-09-07
WO2001055311A2 (fr) 2001-08-02
WO2001055315A3 (fr) 2002-02-07
WO2001055303A2 (fr) 2001-08-02
WO2001055201A8 (fr) 2001-09-07
WO2001055328A2 (fr) 2001-08-02
WO2001055355A1 (fr) 2001-08-02
WO2001055368A8 (fr) 2001-09-07
WO2001055310A3 (fr) 2001-12-27
WO2001055206A1 (fr) 2001-08-02
CA2394039A1 (fr) 2001-08-02
CA2395827A1 (fr) 2001-08-02
WO2001055208A1 (fr) 2001-08-02
CA2392398A1 (fr) 2001-08-02
WO2001055318A8 (fr) 2001-09-07
WO2001055448A8 (fr) 2001-09-07
CA2395858A1 (fr) 2001-08-02
AU2001241409A1 (en) 2001-08-07
WO2001055328A8 (fr) 2001-09-07
WO2001055324A3 (fr) 2002-01-24
WO2001059064A2 (fr) 2001-08-16
CA2395671A1 (fr) 2001-08-02
CA2392757A1 (fr) 2001-08-02
WO2001055322A2 (fr) 2001-08-02
WO2001054473A8 (fr) 2001-09-07
WO2001055302A3 (fr) 2002-02-14
WO2001055323A3 (fr) 2002-05-10
CA2395872A1 (fr) 2001-08-02
CA2395734A1 (fr) 2001-08-02
WO2001055314A8 (fr) 2001-09-07
AU2001241408A1 (en) 2001-08-07
CA2397839A1 (fr) 2001-08-02
WO2001055325A8 (fr) 2001-12-13
AU2001241413A1 (en) 2001-08-07

Similar Documents

Publication Publication Date Title
WO2001055301A2 (fr) Acides nucleiques, proteines et anticorps
WO2001090304A2 (fr) Acides nucleiques, proteines et anticorps
WO2002000677A1 (fr) Acides nucleiques, proteines et anticorps
WO2001055317A2 (fr) Acides nucleiques, proteines et anticorps
WO2002077186A2 (fr) Proteines secretees par l'etre humain
WO2001055326A2 (fr) Acides nucleiques, proteines et anticorps
WO2001055441A2 (fr) Acides nucléiques, protéines et anticorps
EP1370651A1 (fr) 70 proteines humaines secretees
EP1259526A2 (fr) Acides nucleiques, proteines et anticorps
WO2001055167A1 (fr) Acides nucleiques, proteines et anticorps
WO2002057420A2 (fr) 50 proteines secretees humaines
WO2001055162A1 (fr) Acides nucleiques, proteines et anticorps
EP1261619A1 (fr) Acides nucleiques, proteines et anticorps
EP1254217A2 (fr) Acides nucl iques, prot ines et anticorps
EP1261742A2 (fr) Acides nucleiques, proteines et anticorps

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 31/2001 UNDER "PUBLISHED", ADD "WITH SEQUENCE LISTING PART OF DESCRIPTION PUBLISHED SEPARATELY IN ELECTRONIC FORM AND AVAILABLE UPON REQUEST FROM THE INTERNATIONAL BUREAU."

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2001926334

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001926334

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)